Vorinostat (SAHA, MK0683)

Catalog No.S1047

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.

Price Stock Quantity  
USD 191 In stock
USD 147 In stock
USD 220 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Vorinostat (SAHA, MK0683) Chemical Structure

Vorinostat (SAHA, MK0683) Chemical Structure
Molecular Weight: 264.3

Validation & Quality Control

Product Use Citation(97)

Customer Product Validation(20)

Quality Control & MSDS

Related Compound Libraries

HDAC Inhibitors with Unique Features

Product Information

  • Compare HDAC Inhibitors
    Compare HDAC Products
  • Research Area
  • Vorinostat (SAHA, MK0683) Mechanism
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.
Targets HDAC [1]
(Cell-free assay)
IC50 ~10 nM
In vitro Vorinostat inhibits the activities of HDAC1 and HDAC3 with IC50 of 10 nM and 20 nM, respectively. Vorinostat also results in a marked hyperacetylation of histone H4. [1] Vorinostat inhibits the growth of three prostate cancer cell lines LNCaP, PC-3 and TSU-Pr1 at micromolar concentrations (2.5-7.5 μM), and induces dose-dependent cell death in LNCaP cells. [2] Vorinostat treatment in MCF-7 cells inhibits cell proliferation at an IC50 of 0.75 μM resulting in the accumulation of cells in the G1 and G2-M phase of the cell cycle. Vorinostat also induces differentiation in the estrogen receptor-negative cell line SKBr-3 and the retinoblastoma-negative cell line MDA-468. [3] Vorinostat treatment at 1 μM for 8 hours or more is sufficient to irreversibly induce apoptosis of human multiple myeloma (MM) cells. The gene expression profiles of Vorinostat treated MM cells are not hallmarked by global transcriptional activation, but by coordinated transcriptional changes of specific functional groups of genes such as cytokine-induced proliferative/survival signaling cascades, oncogenes-tumor suppressor genes, regulators of apoptosis, DNA synthesis-repair and cell cycle, and proteasome-ubiquitin function. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
A20NF;SOlJMcW6jc3WgRZN{[Xl?MVqxJIg>NVTHZYdRTE2VTx?=M{\vNoFvfGlvSFTBR|Eh[WO2aY\peJkhf2m2aDDJR|UxKG:oIECuNVEzKM7:TR?=MUKxNVk3ODR6OR?=
Friend leukemic cellM1XScGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkTUOVAh|ryPNV73dFZHPzJiaB?=NHXaU2tFVVORM1m2XGlEPTB;MD65PUDPxE1?MWOxNlExQTlzMx?=
K562NHX1RotMcW6jc3WgRZN{[Xl?NWnNW5l6PiCqNWrKbVluTE2VTx?=MV;Jcohq[mm2aX;uJI9nKGi3bXHuJIhqe3SxbnWg[IVi[2W2eXzhd4UhMG2reIT1doUhd2ZiSFTBR|Eh[W6mIFjERWMzMSC5aYToJGlEPTBib3[gNE4xOSEQvF2=MlTNNVI1OTl|OEC=
HT1080MmXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH74OHo4OiCqNH;rdYZFVVORM1Wxe2lEPTB;Mj60JO69VQ>?NUfuXGM2OTJ{N{CxO|U>
H1299NWfyO2NJU2mwYYPlJGF{e2G7NIrVVXMzOCCvaX6=NYrLTZVHTE2VTx?=MmPmTY5pcWKrdH;yfUBi[3Srdnn0fUBi\2GrboP0JGhFSUNiZX76fY1mKHerdHigTWM2OCCxZjCwMlE6PCEQvF2=M3LKSVE1PTJzNEKy
H1299NVzPbnhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV3CT4tDPzJiaB?=M4LXUmROW09?NIXlZ4dKSzVyPUeuNlQh|ryPMVGxOFUzOTR{Mh?=
HeLaMlz0T4lv[XOnIFHzd4F6NY\iSXdUOzBibXnuM3PiO2lvcGmkaYTvdpkh[2:wY3XueJJifGmxbjDh[4FqdnO2IHjpd5RwdmViZHXhZ4V1gWyjc3Wge4l1cCCLQ{WwJI9nKDBwMkig{txONYryZmhvOTV4MEO5OFk>
LOX-IMVIM1HleWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWS0PEBpMn7xTWM2OD1zLkOg{txOM3;B[lE2PzF3NEew
NCI-H226NWLt[ItuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{K1UlQ5KGh?M4Tn[mlEPTB;Mj62JO69VQ>?MVmxOVcyPTR5MB?=
RXF-631LNXn2Um1oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoPpOFghcA>?NESxR3BKSzVyPUKg{txOMUixOVcyPTR5MB?=
SNB-78M1\kUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF\RTI41QCCqMkHXTWM2OD1zNjFOwG0>NFrKdncyPTdzNUS3NC=>
St-4NWrMSIk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIHQOHE1QCCqNUiwO4N4UUN3ME21MlIh|ryPMkC5NVU4OTV2N{C=
ARP1NXSwNIJMTnWwY4Tpc44hSXO|YYm=MWeyJO69VQ>?M4\lXFYhcA>?M2Dycmlv\HWldHnvckBw\iCSMkHXRWYyKGenbnWg[ZhxemW|c3nvci=>MUOxOFc{PDhyNh?=
CEMM4G4[mtqdmG|ZTDBd5NigQ>?NX6xSlBMOSCqM4rWZmROW09?M3G0O2lvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD6zN{DPxE1?MXKxOlQzODB4NB?=
HCT15Ml3YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2PGfFQ5KGh?NFTZTolIUTVyPUCuPFIh|ryPMkf2NVY4OjN{Mke=
NCI-H23NH7LNWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnLMOFghcA>?NXfnPWVXT0l3ME2wMlkzKM7:TR?=NETFOmEyPjd{M{KyOy=>
GM15850Ml7RT4lv[XOnIFHzd4F6M3LVeFIvPSEQvF2=NFewVZQ6PiCqMljlSG1UVw>?MULJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iaHnzeI9v\SCKMzDsfZNqdmViMUSgZYNmfHmuYYTpc44hd2ZiRmjOJIdmdmV?NEnSUlkyPjl{MUO2Oy=>
GM15850M3Lwb2tqdmG|ZTDBd5NigQ>?NWqyNlM6Oi53IN88US=>NUX5SVZNQTZiaB?=NHrJUIZFVVORMkTLTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViSESgcJl{cW6nIEWgZYNmfHmuYYTpc44hd2ZiRmjOJIdmdmV?NXLWU5J{OTZ7MkGzOlc>
GM15850MoixT4lv[XOnIFHzd4F6MYiyMlUh|ryPM1nzb|k3KGh?NEnJOpdFVVORMm\ITY5pcWKrdHnvckBw\iCKRFHDJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViSESgcJl{cW6nIEGyJIFk\XS7bHH0bY9vKG:oIF\YUkBo\W6nM3fYO|E3QTJzM{[3
GM15850NYXudmZ[U2mwYYPlJGF{e2G7NV3Nb2tXOi53IN88US=>NH7IXXQ6PiCqM3q5S2ROW09?MX3Jcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iaHnzeI9v\SCKMzDsfZNqdmViOTDhZ4V1gWyjdHnvckBw\iCIWF6g[4Vv\Q>?M{DNPFE3QTJzM{[3
GM15850M1vGR2tqdmG|ZTDBd5NigQ>?MXKyMlUh|ryPMl7kPVYhcA>?M4jwWGROW09?M{SyfGlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDobZN1d26nIFi0JIx6e2mwZTC4JIFk\XS7bHH0bY9vKG:oIF\YUkBo\W6nNFjG[W8yPjl{MUO2Oy=>
GM15850MXLLbY5ie2ViQYPzZZk>M1rv[VIvPSEQvF2=MoPRPVYhcA>?Mn7jSG1UVw>?NH3jRpNKdmirYnn0bY9vKG:oIFjERWMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgNVYh[WOndInsZZRqd25ib3[gSnhPKGenbnW=NFixZ|cyPjl{MUO2Oy=>
U937M3HkeGZ2dmO2aX;uJGF{e2G7NU\OUWllPSEQvF2=MXuyOEBpMVPEUXNQMYTD[YxtKGO7Y3zlJIFzemW|dDDifUBi[2O3bYXsZZRqd25iYYSgV{9IOi:PIIDoZZNmM1fp[lE4ODB2N{G4
H661NUPPUIsyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmDmOFghcA>?MX\JR|UxRTFizszNMUmxO|E2PzByOR?=
U937Mn7ZSpVv[3Srb36gRZN{[Xl?M3nEc|Uh|ryPNVzEcYFqOjRiaB?=MW\EUXNQNFHZcXpKdmO{ZXHz[UBqdiCqaYP0c45mKEh|IHHj[ZR6dGG2aX;uMVixO|Q1Pzd3MB?=
U937NVzOO|ZGTnWwY4Tpc44hSXO|YYm=MXWxJO69VQ>?M2K4VVI1KGh?NYnSeG5WTE2VTx?=NEjTUmlG\m[nY4Sgc44h[WyyaHGgeJVjfWyrbjDhZ4V1gWyjdHnvci=>NYLpS2ptOTd2NEe3OVA>
RAW264.7NED0fJZHfW6ldHnvckBCe3OjeR?=M2X6VlExKM7:TR?=NHnufGwzPGh?Mo\ne4F1\XJ?NIW5dmNKdmirYnn0bY9vKG:oIFzQV{1{fGmvdXzheIVlKFSQRnHsdIhiKHC{b3T1Z5Rqd25id3n0bEBKSzVyIH;mJFAvPzZizszNMlXRNVc1Pzd3MUi=
RAW264.7MmPBSpVv[3Srb36gRZN{[Xl?M2fQPFExKM7:TR?=MXGyOIg>MlT0e4F1\XJ?NWH1WHU2UW6qaXLpeIlwdiCxZjDMVHMue3SrbYXsZZRm\CCQTzDwdo9lfWO2aX;uJJdqfGhiSVO1NEBw\iBzLki4JO69VQ>?M1WxO|E4PDd5NUG4
SC9M3\ReWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVW0PEBpM2nwbGlEPTB;MD62NFYh|ryPM{T6OFE4PTB5MkG5
ST14ANX\5PGluTnWwY4Tpc44hSXO|YYm=NGXjSYs2KG6PM1S3XlczKGh?MYXJcoNz\WG|ZTDpckBTTVOWL17SV2YhdVKQQTDlfJBz\XO|aX;uNXrhc4FJOTd3NkW5PVM>
ST14ANILvdllHfW6ldHnvckBCe3OjeR?=NUnER5FyPSCwTR?=Mn3hO|IhcA>?NXn4cppoUW6lcnXhd4UhcW5iRULGNUBuWk6DIHX4dJJme3Orb36=MnHCNVc2PjV7OUO=
PANC1NUDLUZNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXqxJO69VQ>?MV\JR|UxRTBwNEWg{txOMmjFNVc2QDh5NES=
PANC1M3vXOGZ2dmO2aX;uJGF{e2G7NHPjVWYyKM7:TR?=NVL2XGN2OjRiaB?=MlHWTY5kemWjc3WgbY4heDJzV1HGNU9EUVBzIHflcoUh\XiycnXzd4lwdg>?MlnKNVc2QDh5NES=
PANC1NFfXOIhHfW6ldHnvckBCe3OjeR?=MUmxJO69VQ>?MV2yOEBpNVjmbIJOUW6lcnXhd4UhcW5icEK3b4lxOSCpZX7lJIV5eHKnc4Ppc44>MWWxO|U5QDd2NB?=
PT45NXf2NGFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoPSTWM2OD12IN88US=>NIH3OJoyPzV6OEe0OC=>
ACHNMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYmyNUBpM3;0W2dKPTB;MD62OUDPxE1?MkD4NVc3PjJ4ME[=
PC3MmO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF2yNZUzOSCqM2j6Z2dKPTB;MD63NUDPxE1?MkXJNVc3PjJ4ME[=
A431MVLDfZRwfG:6aXOgRZN{[Xl?MU[3NkBpNXWyO5VbUUN3ME20MlIh|ryPM1fBRlE4PjlzN{[z
Cal27MUfDfZRwfG:6aXOgRZN{[Xl?M1G1SlczKGh?MW\JR|UxRTNwMjFOwG0>MVixO|Y6OTd4Mx?=
CCRF-CEMMVfDfZRwfG:6aXOgRZN{[Xl?MnTaO|IhcA>?M2TIRmlEPTB;MD64JO69VQ>?NXTHW5dmOTd4OUG3OlM>
EOL1MnTVR5l1d3SxeHnjJGF{e2G7NWLQN3NJPzJiaB?=MYXJR|UxRTFizszNM{TLflE4PjlzN{[z
Hec-1-AMUnDfZRwfG:6aXOgRZN{[Xl?NX\v[YRmPzJiaB?=M1f5UWlEPTB;MTFOwG0>MoXWNVc3QTF5NkO=
HeLaMn;zT4lv[XOnIFHzd4F6NH3lelcyOCEQvF2=MlnuN|AhdWmwNH;XU5ZFVVORM2r0XmlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgTGRCSzFid3n0bEBKSzVyIH;mJFAvODJizszNMUGxO|Y6OTd4Mx?=
RKOp21NH65OI1EgXSxdH;4bYMhSXO|YYm=NGHBcHk4OiCqMnLTTWM2OD1zLke2JO69VQ>?MXWxO|Y6OTd4Mx?=
Saos2M2ntT2N6fG:2b4jpZ{BCe3OjeR?=NYf5S3pkPzJiaB?=NUL1cXRKUUN3ME2yMlMh|ryPNXnWS3NoOTd4OUG3OlM>
SK-OV-3NUG1PXdVS3m2b4TvfIlkKEG|c3H5NInHVYE4OiCqMlPCTWM2OD1{LkKg{txOMXWxO|Y6OTd4Mx?=
U87MGMnnhR5l1d3SxeHnjJGF{e2G7M2H0XFczKGh?MVzJR|UxRTFzIN88US=>NITje2gyPzZ7MUe2Ny=>
NUGC3MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3nnXVUh|ryPNX7hO21oOjRiaB?=NIXxenNIUTVyPUKuO|kh|ryPNXvXc2xZOTd7MES4OFM>
CCD1059SKMnHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHTuOWVKSzVyPUSzMlUh|ryPMXuxPFI1PzV3NB?=
HepG2MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVfJR2xqUUN3ME2wMlAxODZizszNMl3zNVgzPDd3NUS=
HT1080M2naWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYroO4lYUUN3ME2wMlAxOjRizszNNGLGPZIyQDJ2N{W1OC=>
SKBR3MnvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnJR|UxRTBwODFOwG0>MYexPFI1PzV3NB?=
SNB78MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYPGUndzTUN3ME2xOkDPxE1?M2XLW|E5OjR5NUW0
SQ20BMoTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoHGTWM2OD1|IN88US=>MVexPFI1PzV3NB?=
St4M2nzSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1uybWVEPTB;NT6yJO69VQ>?NWHhfotwOTh{NEe1OVQ>
MCF7MkjPSpVv[3Srb36gRZN{[Xl?M4\LNFExKM7:TR?=NHzEXII5KGh?MWPEUXNQMo[xTY5lfWO2aX;uJI9nKHS3YoXsbY4hcHmyZYLhZ4V1gWyjdHnvci=>MlzNNVgzPjl{Mk[=
HEK293NIDM[oJMcW6jc3WgRZN{[Xl?NWjNdm5lOSCqNX7I[Y15TE2VTx?=MXjJcohq[mm2aX;uJI9nKEiGQVOxJJdqfGhiSVO1NEBw\iByLkCzJO69VQ>?MVyxPFMxQDV4Mx?=
HEK293NWH5fYFTU2mwYYPlJGF{e2G7M2nqcVEhcA>?NH3BNZVFVVORMkTNTY5pcWKrdHnvckBw\iCKRFHDN{B4cXSqIFnDOVAhd2ZiMD6wOVch|ryPNYexcGoxOTh|MEi1OlM>
G401Moi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3fDZVczKGh?MYLEUXNQMnf0TWM2OD1zIN88US=>Mof6NVg{PzB|N{O=
HeLaM{jBV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mm[3O|IhcA>?MV;EUXNQMYHJR|UxRTBwNE[g{txOM1;yflE5OzdyM{ez
Human renal epithelial cellMUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWi3NkBpNFXEO2JFVVORNG\ydIdKSzVyPUG0JO69VQ>?MYWxPFM4ODN5Mx?=
U937MkHaSpVv[3Srb36gRZN{[Xl?NWXGcmV[PSEQvF2=M{iwfFI1KGh?Mm\4TY5lfWO2aX;uJI9nKGirc4TvcoUhUDRiaInw[ZJi[2W2eXzheIlwdg>?Ml;ZNVg{QDF{M{i=
U937M13QU2Z2dmO2aX;uJGF{e2G7NHvwc2s2KM7:TR?=MYOyOEBpM3T1SWlv\HWldHnvckBw\iCjbIDoZUB1fWK3bHnuJIh6eGW{YXPleJlt[XSrb36=NEX3Rm8yQDN6MUKzPC=>
U937NG[0[2RHfW6ldHnvckBCe3OjeR?=Mm\pOUDPxE1?NXL0XnlEOjRiaB?=NEHBfFFKdmS3Y4Tpc44hd2ZicEKxJIV5eHKnc4Ppc44>MYKxPFM5OTJ|OB?=
U937NXzNfGRzTnWwY4Tpc44hSXO|YYm=NI\PS|M2KM7:TR?=Mk[wNlQhcA>?NWXuU2Q5UW6mdXP0bY9vKG:oIHHwc5B1d3Orcx?=NGXqNnoyQDN6MUKzPC=>
U937M3;UR2Z2dmO2aX;uJGF{e2G7MYG1JO69VQ>?NUPnUnBHOjRiaB?=NI\l[pNKdmS3Y4Tpc44hd2ZiZ4LhcpVtd2O7dHnjJIRq\m[ncnXueIlifGmxbh?=MXSxPFM5OTJ|OB?=
U937NWjyepA6U2mwYYPlJGF{e2G7MVW1JO69VQ>?NWrLbYx6OjRiaB?=MX;Jcohq[mm2aX;uJI9nKGi3bXHuJGhFSUNzMVixPFM5OTJ|OB?=
U937MoraT4lv[XOnIFHzd4F6NULFfJRTPSEQvF2=M3LGV|I1KGh?NVLR[3VRUW6qaXLpeIlwdiCxZjDoeY1idiCKRFHDOC=>NV3NXIZGOTh|OEGyN|g>
HEK-TEM2PUb2Z2dmO2aX;uJGF{e2G7MWW1JO69VQ>?MUG2bC=>Mo\LSG1UVw>?MmX5TY5kemWjc3WgbY4hcGm|dH;u[UBJOyCjY3X0fYxifGmxbh?=NX3oVGhCOTh2M{SxOFQ>
HPDE6c7M4rDO2N6fG:2b4jpZ{BCe3OjeR?=MWe1NEDPxE1?M1GxdlczKGh?MknHSG1UVw>?M2[xNmlEPTB;MT6zJO69VQ>?NFPlWGsyQDR7NES2Ny=>
Human microvascular epithelial cellMWXDfZRwfG:6aXOgRZN{[Xl?MnHpOVAh|ryPMljoO|IhcA>?NXOzZoQ2TE2VTx?=MlHPTWM2OD1zLkOg{txOM{fMRlE5PDl2NE[z
Hup T3MmnDR5l1d3SxeHnjJGF{e2G7NV73TY56PTBizszNNWnDSHNMPzKqMU\EUXNQNGO1XYVKSzVyPUCuPEDPxE1?MXGxPFQ6PDR4Mx?=
Mia Paca2NV\n[W5nS3m2b4TvfIlkKEG|c3H5M{DpeVUxKM7:TR?=NFHnUIw4Omh?MlLpSG1UVw>?MnzVTWM2OD1zLkGg{txONV\iS|BFOTh2OUS0OlM>
Panc 04.03MX;DfZRwfG:6aXOgRZN{[Xl?NWrhOJM1PTBizszNM4LSTFczcA>?NYnn[HNqTE2VTx?=M4DBNGlEPTB;MT6yJO69VQ>?NXzGUJE3OTh2OUS0OlM>
SU 86.86NHrXcm5EgXSxdH;4bYMhSXO|YYm=M1PKOlUxKM7:TR?=MVe3Nog>M2r6bmROW09?M3fMWmlEPTB;MT6zJO69VQ>?Mmf4NVg1QTR2NkO=
HEK293MVTLbY5ie2ViQYPzZZk>MonMN{BpMXPJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IFjERWM3KGW6cILld5Nqd25id3n0bEBKSzVyIH;mJFAvODF7IN88US=>NFzoeY4yQDV3OE[2PS=>
HeLaM2\FXGtqdmG|ZTDBd5NigQ>?NIjGOXYzKGh?NEHpUoVKdmirYnn0bY9vKG:oIH71Z4xm[XJiSFTBR{B4cXSqIFnDOVAhd2ZiMD6wPFMh|ryPNX\JWVYyOTh3NUi2Olk>
RAW264.7Mnf5SpVv[3Srb36gRZN{[Xl?MXWyJO69VQ>?M1\s[FMvPSCqMV;EUXNQNY\WWIRmSW62aX3hcIFzcWGuIHHjeIl3cXS7IHHnZYlve3RiUHzhd41w\Gm3bTDmZYxkcXCjcoXtJIlv\mWldHXkJJdqfGhiSVO1NEBw\iByLkGxJO69VQ>?M3LiVVE5PjR2OU[5
NB4NHjZcpk1QGh?NGXvcoVFVVORNGXaUldKSzVyPUCuOkDPxE1?M3[2elE5PzJ|M{S5
HEK293NFPrTY1HfW6ldHnvckBCe3OjeR?=NY\sXpllOTBizszNMl7DNlQhcA>?NGjKd2VFVVORM2W4VmFkfGm4YYTpc44hd2ZibX;1d4UhX262M3Ggd4lodmGuaX7nJIV5eHKnc4Pl[C=>NYnmclI1OTlyMkK2O|U>
HCT116NVe3Uo1DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmXxO|JpMn3lSG1UVw>?MVzJR|UxRTBwM{Gg{txOM2LvTVE6ODh2Mkm0
HeLaM4HpXWtqdmG|ZTDBd5NigQ>?MkHWNkDPxE1?MX:zNEBucW5?M3HoSmROW09?NEDvbFVKdmirYnn0bY9vKG:oIFjERWMzKGmwIHj1cYFvKEinTHGgZ4VtdHNid3n0bEBKSzVyIH;mJFAvOSEQvF2=Mlr0NVkxQDR{OUS=
IGROV1MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2LHVVczKGh?MX;EUXNQM2\4fWlEPTB;Mj6yJO69VQ>?NG\afFUyQTB6NEK5OC=>
IGROV1Mnq5T4lv[XOnIFHzd4F6M1nP[VUh|ryPMoSwNlQhcA>?MVnEUXNQMUnJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO|ZXSgZZMheDV|IHHj[ZR6dGG2aX;uMVmxPVA5PDJ7NB?=
IGROV1MX;LbY5ie2ViQYPzZZk>Mn\jNVAh|ryPMVW0JIg>NIrPb5dFVVORMVzJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO|ZXSgZZMhcGm|dH;u[U1JPCCjY3X0fYxifGmxbh?=NHzKfpoyQTB6NEK5OC=>
IGROV1NX;rdIpCU2mwYYPlJGF{e2G7MXmxNEDPxE1?M323flQhcA>?MX7EUXNQMofGTY5pcWKrdHnvckBw\iCKRFHDOkBie3Onc4Pl[EBieyCjbIDoZU11fWK3bHnuJIFk\XS7bHH0bY9vMo\jNVkxQDR{OUS=
T24M3\iVWtqdmG|ZTDBd5NigQ>?M13BbVMhcA>?MlnhTY5lfWO2aX;uJI9nKGirc4TvcoUhUDNiYXPleJlt[XSrb36ge4l1cCCHQ{WwJI9nKDBwMUKg{txOM4HCSlE6ODh2M{m1
T24MnjFT4lv[XOnIFHzd4F6NYfSTYg2OyCqMl;aTY5lfWO2aX;uJI9nKGGucHjhJJR2[nWuaX6gZYNmfHmuYYTpc44hf2m2aDDFR|UxKG:oIECuNlUh|ryPMUmxPVA5PDN7NR?=
HeLaM4Hk[WtqdmG|ZTDBd5NigQ>?NH24NYUyPSCvaX6=M2TnV2ROW09?M{O4NmlvcGmkaYTpc44hd2ZiSFTBR|Yh\nKxbTDueYNt\WG{IHX4eJJi[3Rid3n0bEBKSzVyIH;mJFAvODh3NTFOwG0>M{DoSlE6ODl|OEi0
HeLaNEnGfG1McW6jc3WgRZN{[Xl?NGPp[lIyPSCvaX6=M1vrRWROW09?NVLuOYNJUW6qaXLpeIlwdiCxZjDISGFEQCCocn;tJI52[2ynYYKg[Zh1emGldDD3bZRpKEmFNUCgc4YhOS56NjFOwG0>MWixPVA6Ozh6NB?=
NCI-H69M{TsXGN6fG:2b4jpZ{BCe3OjeR?=MoHFO|IhcA>?NIfRWHhFVVORMXrJR|UxRTJwME[g{txOMkfZNVkxQTN6OES=
SKMES1MXLDfZRwfG:6aXOgRZN{[Xl?NYTk[3l5PzJiaB?=MlT6SG1UVw>?M1;UdGlEPTB;Mj60NkDPxE1?M2HzVlE6ODl|OEi0
S2NVn5dpRKU2mwYYPlJGF{e2G7NYLTXmVqOC5zLUGwJO69VQ>?MlnzNUBpNXP4VWlJUW6qaXLpeIlwdiCxZjDQcIF{dW:maYXtJIZidGOrcHHyeY0hUESDQ{Gg[ZhxemW|c3XkJJdqfGhiSVO1NEBw\iByLkC1PUDPxE1?MXSxPVMyPzR3MB?=
SHSY5YMmfNT4lv[XOnIFHzd4F6MYmxNEDPxE1?MlfEOFghcA>?M2XFfmROW09?M4rPUmlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD61JO69VQ>?MmDwNVk{PDRzN{W=
SHSY5YMo\MR5l1d3SxeHnjJGF{e2G7NXvkd|B2OTBizszNNFH1XFU1QCCqNHjSOm5FVVORNXnMdHlNUUN3ME2yJO69VQ>?MVuxPVM1PDF5NR?=
DMS114NHXBOXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4D0OlQ5KGh?NI\0Z41IUTVyPUKuPUDPxE1?MV2xPVQyQTJyNR?=
HBC5NYnpXWR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MljIOFghcA>?NYjTW5BMT0l3ME2xO{DPxE1?NVz5cWZYOTl2MUmyNFU>
SNB78MkPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4\JTlQ5KGh?M3Kzc2dKPTB;MU[g{txOMVOxPVQyQTJyNR?=
HeLaM4\LVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MY[3NkBpNWnGelZrTE2VTx?=MX;JR|UxRTBwNE[g{txOMVixPVQ1OTh2Nh?=
BHKNXH3U5JGU2mwYYPlJGF{e2G7MWK1JO69VQ>?MnnqNlQhcA>?NWDINmJKTE2VTx?=MYHJcohq[mm2aX;uJI9nKEiGQVO3JIV5eHKnc4Pl[EBie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDwcIF{dWFibXXtZpJidmViRnTlcJRiPTB6IFPGWHIheHKxdHXpci=>NEDtOm4yQTl4Nke4PS=>
CFBE41o-M4f2VGtqdmG|ZTDBd5NigQ>?NVr2OlA6PSEQvF2=MUm4JIg>M1TvZWROW09?NETlbmlKdmirYnn0bY9vKG:oIFjERWMh[XO|ZYPz[YQh[XNiaInw[ZJi[2W2eXzheIlwdiCxZjDobZN1d26nIFizNFTKTHQyQTl4Nke4PS=>
CFBE41o-MWnLbY5ie2ViQYPzZZk>M3G1XlUh|ryPM1y0eFQhcA>?NVn6d45lTE2VTx?=MlzSTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIH31eIFvfCCIZHXseIE2ODhiQ1\UVkBxem:2ZXnuJIxmfmWuM3PqflE6QTZ4N{i5
CFBE41o-NVPX[49lU2mwYYPlJGF{e2G7M{PtUFEh|ryPMVqxJIg>NUXnOJlETE2VTx?=MYjJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iQ1\UVkBxem:2ZXnuJIxmfmWuNV\Db5Y{OTl7Nk[3PFk>
Primary bronchial epithelial cellNV\6Vmk3U2mwYYPlJGF{e2G7NEjDT|YyKM7:TR?=NH;ndoozPCCqNH:wVXdFVVORMWrJcohq[mm2aX;uJI9nKEiGQVO3JIF{e2W|c3XkJIF{KGmwZIXjeIlwdiCxZjDteZRidnRiRnTlcJRiPTB6IFPGWHIheHKxdHXpckBieGmlYXygd5Vz\mGlZTDsc4NidGm8YYTpc44>MkDYNVk6PjZ5OEm=
CFBE41o-MYPLbY5ie2ViQYPzZZk>NYrUdVJsOSEQvF2=MX61JIRigXN?MWHEUXNQNWfFTGNoUW6qaXLpeIlwdiCxZjDISGFEPyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckB{fGGkaXzpfoF1cW:wIH;mJGZl\Wy2YUWwPEBETlSUIIDyc5RmcW5?M1mxOVE6QTZ4N{i5
CFBE41o-NGOwc|hMcW6jc3WgRZN{[Xl?NGTpNWYyKM7:TR?=NYj3TGVYOjRiaB?=NHnqc|lFVVORM4HP[mlvcGmkaYTpc44hd2ZiSFTBR|ch[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gSoRmdHSjNUC4JGNHXFJicILveIVqdiC2cnHm[olkc2mwZx?=NYnaTZhpOTl7Nk[3PFk>
CFBE41o-MVrLbY5ie2ViQYPzZZk>MoLLOUDPxE1?NGPTXFgzPCCqMXzEUXNQNEDs[odKdmirYnn0bY9vKG:oIFjERWM4KGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJJJifGVib3[gcYF1fXKjdHnvckBw\iCFRmTSJJBzd3SnaX6geI8hcXS|IHfsfYNw\m:{bR?=MWmxPVk3Pjd6OR?=
CFBE41o-M3Xnd2tqdmG|ZTDBd5NigQ>?MWq1JO69VQ>?NFXSTJAzPCCqNHn4ZopFVVORMXfJcohq[mm2aX;uJI9nKEiGQVO3JIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIIP0ZYJqdGm2eTDv[kBH\GWudHG1NFghS0[WUjDwdo91\WmwM2G4ZlE6QTZ4N{i5
CFBE41o-M3\sZ2tqdmG|ZTDBd5NigQ>?NYLDSHpZPSEQvF2=NIjnXWEzPCCqNIfpOGdFVVORM{\4VWlvcGmkaYTpc44hd2ZiSFTBR|ch[XO|ZYPz[YQh[XNiY3;ydoVkfGmxbjDv[kBufXSjboSgSoRmdHSjNUC4JGNHXFJidILh[oZq[2urbnegeI8h[2WubDDzeZJn[WOnIHHzJIdtgWOxZn;ycS=>NXrx[Vh3OTl7Nk[3PFk>
Primary bronchial epithelial cellMl34T4lv[XOnIFHzd4F6NXzrR4IyPSEQvF2=M4Tnc|I1KGh?MYPEUXNQNVfXNIRQUW6qaXLpeIlwdiCxZjDISGFEKGG|c3Xzd4VlKGG|IHnu[JVkfGmxbjDv[kBufXSjboSgSoRmdHSjNUC4JGNHXFJicILveIVqdiCjcHnjZYwhe3W{ZnHj[UBtd2OjbHn6ZZRqd25?Ml25NVk6PjZ5OEm=
Primary bronchial epithelial cellM4fwNmtqdmG|ZTDBd5NigQ>?MWCxJO69VQ>?MVG5OkBpMXPEUXNQMXLJcohq[mm2aX;uJI9nKEiGQVO3JIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIIPoc5J1KGOrcnP1bZQh[3W{cnXueJM>NEnYVm8yQTl4Nke4PS=>
BxPC3NYn0[nBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnrxO|IhcA>?NGPXTGNKSzVyPUKuO{DPxE1?NWHYR29GOjBzNEO3O|g>
CAL27MmC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEHWZpk4OiCqNGn3OZFKSzVyPUOuO|Ih|ryPM3PGRVIxOTR|N{e4
Capan1NEL0SG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{\WcFczKGh?M1;GZWlEPTB;Nz6zJO69VQ>?MX[yNFE1Ozd5OB?=
HCC827M4XPTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXi3NkBpNVXBW5ZGUUN3ME2xMlgh|ryPNWfKOHBNOjBzNEO3O|g>
LNCAPNVfrcll4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXe3NkBpM2rFZmlEPTB;MD61PEDPxE1?MnGxNlAyPDN5N{i=
NCI-H2122MniwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUK3NkBpMkThTWM2OD15LkWg{txOMWiyNFE1Ozd5OB?=
NCI-H358NWX0TpB5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3TCUFczKGh?NVfHUXFTUUN3ME2yMlUh|ryPM{W5WVIxOTR|N{e4
SCC15NU\OS2k2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGjOPXk4OiCqNEHyOoVKSzVyPUKuOFkh|ryPNX\0WmFjOjBzNEO3O|g>
SCC25NYWxU4lOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlXNO|IhcA>?NY\uW45YUUN3ME2xMlk{KM7:TR?=M3H3S|IxOTR|N{e4
SKHEP1MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4PhdVczKGh?NX;qS29rUUN3ME2zMlQ3KM7:TR?=MUeyNFE1Ozd5OB?=
BJMn7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MofUNVAxKM7:TR?=NWXVRZloPDhiaB?=M2LNUGROW09?NVPhVmh[T3Kxd4ToJIlvcGmkaYTpc44h[XRiMD6wOUB1dyBzMECgeW0>M4PGV|IxOTR|OESw
MUFMlz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWm1eJQ5OTByIN88US=>NY\sU2RVPDhiaB?=M{nKc2ROW09?MnHMS5Jwf3SqIHnubIljcXSrb36gZZQhOC5yNTD0c{AyODBidV2=NEe0Z3EzODF2M{i0NC=>
Caco-2Mlj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFrEcGsyODBizszNNWLxbmc6PDiqMWXEUXNQMUnJR|UxRThwMTFOwG0>MoTNNlAyPDN6NEC=
Caco-2Mm\BT4lv[XOnIFHzd4F6Mn[2OUDPxE1?MmP2OEBpMoHuSG1UVw>?NGrqOZVKdmS3Y4Tpc44hd2ZiSFTBR{1u\WSrYYTl[EBpcXO2b37lJIFk\XS7bHH0bY9vKEmFNUCgc4YhOC5yM{eg{txOM2r4bVIxOTR|OESw
Caco-2MYjLbY5ie2ViQYPzZZk>NETRZ4gxNjNzNjDuUUB1dyB|MT62JO69VQ>?NUHKdodtPCCqNGTEbpZFVVORNHnIepBGgCC4aY\vJIlvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{Gge4l1cCCLQ{WwJI9nKDBwMUG5JO69VQ>?NWP5enB3OjBzNEO4OFA>
Caco-2MofwT4lv[XOnIFHzd4F6M2jEbFAvOzF4IH7NJJRwKDNzLk[g{txOM3voPFQhcA>?MnPmSG1UVw>?MV\FfEB3cX[xIHnubIljcXSrb36gc4YhcHWvYX6gTGRCSzNid3n0bEBKSzVyIH;mJFAvOTR5IN88US=>NI\hcXUzODF2M{i0NC=>
Caco-2MoP2T4lv[XOnIFHzd4F6NF;CSXE3NjN{IH7NJJRwKDZ|MjFOwG0>MmftOEBpNGnVU3NFVVORM33W[mV5KH[rdn:gbY5pcWKrdHnvckBw\iCqdX3hckBJTEGFNTD3bZRpKEmFNUCgc4YhOTJwNjFOwG0>NFfIT4EzODF2M{i0NC=>
Caco-2MXXLbY5ie2ViQYPzZZk>MnfxOk4{OiCwTTD0c{A3OzJizszNNFvHRZE1KGh?Mnq0SG1UVw>?Ml7SSZghfmm4bzDpcohq[mm2aX;uJI9nKGi3bXHuJGhFSUN5IIfpeIghUUN3MDDv[kA1OSEQvF2=MWSyNFE1Ozh2MB?=
Caco-2M4rFbWtqdmG|ZTDBd5NigQ>?NXH0eJU4OC5|MU[gcm0hfG9iM{GuOkDPxE1?MVW0JIg>MVzEUXNQM{\UNGV5KH[rdn:gbY5pcWKrdHnvckBw\iCqdX3hckBJTEGFNh?=M4n4b|IxOTR|OESw
HepG2NHOwfG9McW6jc3WgRZN{[Xl?M13RWlUh|ryPMY[2bC=>Mmq4SG1UVw>?NVrI[nBiUW6mdXP0bY9vKG:oIFjERWMudWWmaXH0[YQhcGm|dH;u[UBi[2W2eXzheIlwdg>?NXnLdlBFOjBzNEO4OFA>
HepG2NH[wd5BMcW6jc3WgRZN{[Xl?MoP4OUDPxE1?NFfaXXg3cA>?M{D5XmROW09?MWrJcoR2[3Srb36gc4YhUESDQz3t[YRq[XSnZDDobZN1d26nIHj5dIVz[WOndInsZZRqd25?NVPkbJNMOjBzNEO4OFA>
HepG2MYjLbY5ie2ViQYPzZZk>NIrrSHc2KM7:TR?=MYC2bC=>NYH1V2FqTE2VTx?=NVzZT49xUW6mdXP0bY9vKG:oIFjERWMudWWmaXH0[YQh[WyyaHGteJVjfWyrbjDhZ4V1gWyjdHnvci=>MmDqNlAyPDN6NEC=
HepG2MnHYT4lv[XOnIFHzd4F6M1\mcVUh|ryPNWj5XZdkPmh?NIDCOHNFVVORMmezTY5lfWO2aX;uJI9nKEiGQVOtcYVlcWG2ZXSgTFMwUDRiaHnzeI9v\SCjY3X0fYxifGmxbh?=NXLYPVNZOjBzNEO4OFA>
COLO205NH\p[nhMcW6jc3WgRZN{[Xl?MkTXNVAh|ryPMoHuNlQhcA>?MYrEUXNQM2fDSWlvcGmkaYTpc44hd2ZiSFTBR|Eh[XO|ZYPz[YQh[XNiaX7keYN1cW:wIH;mJIhqe3SxbnWgTFMh[WOndInsZZRqd25id3n0bEBKSzVyIH;mJFIvOiEQvF2=NIjvW4YzODR3MUO3PC=>
SCC4MmnjT4lv[XOnIFHzd4F6M2HB[lEh|ryPNFTweVAzPGh?M1Xze2lvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjD0eYJ2dGmwIHHj[ZR6dGG2aX;uNVHvPWhLOjB2NUKyNlU>
SCC4MWjLbY5ie2ViQYPzZZk>M2HCbVEh|ryPNXrWWWhtOjSqNIrvb|RKdmirYnn0bY9vKG:oIFjERWMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDhZ4V1gWyjdHnvci=>MX6yNFQ2OjJ{NR?=
SCC4NVjRUnlZTnWwY4Tpc44hSXO|YYm=NY\1enUyOSEQvF2=MV:1JI1qdg>?NFzDT3FC\2:waYP0JIFkfGm4aYT5JIF1KF[GUjDhd5Nme3OnZDDhd{BqdmS3Y4Tpc44hd2ZiQ2nQNlQh\2WwZTDlfJBz\XO|aX;uMl\GNlA1PTJ{MkW=
NB4M3TndGZ2dmO2aX;uJGF{e2G7NWjrdFI1PSEQvF2=MVqyOEBpNUDhb5h5TE2VTx?=MlXZR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iYXPjeY12dGG2aX;uJIF1KHC{ZT3HNUBxcGG|ZR?=MlfwNlA1QTF2NEC=
NB4M3fOe2tqdmG|ZTDBd5NigQ>?NV:zdnlnPSEQvF2=Mk\INlQhcA>?MXXEUXNQM1TGRWlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDhZ4V1gWyjdHWgeJVjfWyrbjDs[ZZmdA>?NGHwcHYzODR7MUS0NC=>
NB4M{\RTmZ2dmO2aX;uJGF{e2G7MVq1JO69VQ>?NFTjc2IzPCCqMlLOSG1UVw>?NH;4e5FKdmS3Y4Tpc44hd2ZicEKxW2FHOS:FSWCxJIV5eHKnc4Ppc44>MkLvNlA1QTF2NEC=
NB4MmfZT4lv[XOnIFHzd4F6MV:1JO69VQ>?NFjDRXUzPCCqMlPISG1UVw>?MmL3TY5pcWKrdHnvckBw\iCKRFHDJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViSEOgZYNmfHmuYYTpc44>NYHmW5NsOjB2OUG0OFA>
NUGC3M37HXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoPWS2k2OD1{Lkm0JO69VQ>?NInjS|kzODh3MEm3NS=>
A549MlzBSpVv[3Srb36gRZN{[Xl?M4m4XFUh|ryPM2nWWlMhcA>?NYf4PFRqTE2VTx?=NHThfW1KdmS3Y4Tpc44hd2ZiYYX0c5Bp[We7IHnuJIh2dWGwIFG1OFkh[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iTFOzTWk>MYGyNFg2PTJyOB?=
HUT78M2fMTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYi3NkBpMX\EUXNQNFS0UJRIUTVyPUCuN{DPxE1?M3LqO|IxQDh2MkC4
U937NUPpZmpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYC3NkBpM{LrfWROW09?NFPWRnRIUTVyPUCuN|kh|ryPNF;BfmczODh6NEKwPC=>
A431M2Xoe2N6fG:2b4jpZ{BCe3OjeR?=NVTt[HdtPzJiaB?=MUDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOFMyKGOnbHzzJI93\XKneIDy[ZN{cW6pIFXHSnIhf2m2aDDJR|UxKG:oIESuNkDPxE1?M1z3[lIyODhyNkK5
A549NH63copEgXSxdH;4bYMhSXO|YYm=MWm3NkBpM4LpWGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMhd3[ncnX4dJJme3OrbnegTGRCSyC5aYToJGlEPTBib3[gNU45KM7:TR?=NXi2fJhxOjFyOEC2Nlk>
CAL27M1nOR2N6fG:2b4jpZ{BCe3OjeR?=NILaU5c4OiCqMlrJR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR2FNOjdiY3XscJMhd3[ncnX4dJJme3OrbnegSWdHWiC5aYToJGlEPTBib3[gN{4zKM7:TR?=MX[yNVA5ODZ{OR?=
HeLaNHj3[45EgXSxdH;4bYMhSXO|YYm=M3fqUlczKGh?NF3ybmFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\UyjIHPlcIx{KG:4ZYLlfJBz\XO|aX7nJGhFSUNid3n0bEBKSzVyIH;mJFEvPSEQvF2=NFvnc4MzOTB6ME[yPS=>
Sf21Ml7aT4lv[XOnIFHzd4F6NGrzSWk{KGh?MYPJcohq[mm2aX;uJI9nKE[uYXegeIFo\2WmIHj1cYFvKHKnY3;tZolv[W62IFjERWM5KGW6cILld5Nm\CC5aYToJGlEPTBib3[gNU4zKM7:TR?=MYGyNVA5ODZ{OR?=
SKBR3M2jwRmN6fG:2b4jpZ{BCe3OjeR?=NVjLcpdWPzJiaB?=M1jVfGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNMSlJ|IHPlcIx{KG:4ZYLlfJBz\XO|aX7nJGhGWjJid3n0bEBKSzVyIH;mJFIvPiEQvF2=NG[ydZQzOTB6ME[yPS=>
SKOV3NYew[ohIS3m2b4TvfIlkKEG|c3H5NUfDWmlVPzJiaB?=NHL3endEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUU0:YMzDj[YxteyCxdnXy[ZhxemW|c3nu[{BJTVJ{IIfpeIghUUN3MDDv[kAzNjJizszNMVqyNVA5ODZ{OR?=
COR-L23MmL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXTzV3h5OTBizszNNHThclI4OiCqMWTEUXNQMWPHTVUxRTFwMTFOwG0>NVXiSGE5OjFyOEC2OFc>
DU145MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnHaNVAh|ryPM{PQ[|czKGh?NX7yTmlmTE2VTx?=MWHHTVUxRTFwMEWg{txOM4HsTFIyODhyNkS3
LoVoNFq3Oo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYTtdJRNOTBizszNNIXlRoM4OiCqM2DZdWROW09?MVrHTVUxRTFwNzFOwG0>MWKyNVA5ODZ2Nx?=
MCR5-SV2MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYCxNEDPxE1?NH6yPZo4OiCqMlv3SG1UVw>?MVHHTVUxRTJwMTFOwG0>NW[3TYxxOjFyOEC2OFc>
HCT116NF6zNmtMcW6jc3WgRZN{[Xl?MUKzNEDPxE1?M4jYS|MxKGh?NYDQZVJITE2VTx?=MUnJcohq[mm2aX;uJI9nKEiGQVO2JIF{e2W|c3XkJIF{KGmwZIXjeIlwdiCxZjDhcJBp[S22dXL1cIlvKGGlZYT5cIF1cW:wMX2yNVA5ODZ2Nx?=
HCT116NIfXTGlMcW6jc3WgRZN{[Xl?NY\N[HlbOzBizszNMVKzNEBpM2DlUmROW09?MnXhTY5pcWKrdHnvckBw\iCKRFHDNUBie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gbIl{fG:wZTDIN2s6KGGlZYT5cIF1cW:wM{DFOVIyODhyNkS3
U937M{LqUGtqdmG|ZTDBd5NigQ>?M2i0U|Uh|ryPNFHjfHgzPCCqM4P6cGROW09?M1zSSGlvcGmkaYTpc44hd2ZiaHnzeI9v\SCjY3X0fYx1emGwc3\ldoF{\SCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDv[kBi[2W2eXzheIlwdiCxZjDobZN1d26nIFizJIF1KEt7MUOyNVI6OjR7Mh?=
U937MmHuT4lv[XOnIFHzd4F6Mnf0OUDPxE1?NIX3[XAzPCCqMleySG1UVw>?M3zRSGlvcGmkaYTpc44hd2ZiaHnzeI9v\SCjY3X0fYx1emGwc3\ldoF{\SCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDv[kBi[2W2eXzheIlwdiCxZjDobZN1d26nIFizJIF1KEtzOB?=MX2yNVI6OjR7Mh?=
U937NYLPTHNMU2mwYYPlJGF{e2G7NHjLfVI2KM7:TR?=NEHVNIwzPCCqNFe5OYVFVVORMlv0TY5pcWKrdHnvckBw\iCqaYP0c45mKGGlZYT5cJRz[W6|ZnXyZZNmKGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIH;mJJBidi2jY3X0fYxifGWmIHjpd5RwdmViSESgcIV3\Wx?NGPGc4czOTJ7MkS5Ni=>
U937NWruN|hPU2mwYYPlJGF{e2G7NIjvZnQ2KM7:TR?=MnvKNVUhdWmwNFHqR3hFVVORMnjyTY5pcWKrdHnvckBw\iCqaYP0c45mKGGlZYT5cJRz[W6|ZnXyZZNmKGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIH;mJIhqe3SxbnWgTFMh[WOndInsZZRqd25ibHX2[Yw>MlqxNlEzQTJ2OUK=
A2780NEnM[nNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{fRRVk3KGh?NGTxUXlFVVORNHrQUXhKSzVyPUGuOlIh|ryPNGDifoYzOTZ|NESzNC=>
COLO205NFrqZoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYm5OkBpM4XBZ2ROW09?NUGwc5IzUUN3ME2yMlEzKM7:TR?=NFLk[GMzOTZ|NESzNC=>
Hep3BNV;6e|ljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\ZU4lYPDhiaB?=NVrwfZR5TE2VTx?=MUPHTVUxRTFwMkGg{txOM1XLXFIyPzF{MUS2
GM11272Mn7DSpVv[3Srb36gRZN{[Xl?M3jITFExOCCwTR?=M3f2U|czKGh?M{\NU2ROW09?MVPS[YFkfGm4YYTpc44hd2ZiTXXDdFIhdXW2YX70JIV5eHKnc4Ppc44h[XRiMUCgeI8hOTByIH7NMVOyNVg1ODdzNh?=
CFBE41oNFjCeJRMcW6jc3WgRZN{[Xl?MXe1JO69VQ>?MYTEUXNQMmn0SI94diC{ZXf1cIF1cW:wIH;mJGhFSUN5IHH0JFAvOiC2bzC1JJVONXnhb|JZOjF7OES5OVg>
CFBE41oNHqwb3hHfW6ldHnvckBCe3OjeR?=M{fGR|Eh|ryPNFXyPWczPCCqM2nQZmROW09?M3\oTHJme3SxcnH0bY9vKG:oIFPGWHIh\GWudHHGOVA5KG23dHHueEB1emGoZnnjb4lv\yC2bzDj[YxtKHO3cn\hZ4Uh[XNiZ3z5Z49nd3Kvcx?=NEfrUm0zOTl6NEm1PC=>
DU145NWP6TWZLU2mwYYPlJGF{e2G7M4\LVVIvPSEQvF2=MXmyOEBpMn3ZSG1UVw>?MmHkTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W|c3XkJIF{KHWycnXneYxifGmxbjDv[kBxOjG5YX[xJJBzd3SnaX6g[ZhxemW|c3nvci=>M3\qPFIzOjZyMU[2
DU145M13MTGtqdmG|ZTDBd5NigQ>?MmnOOUDPxE1?M1jzbFI1KGh?MV7EUXNQM1HDeWlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCqaYP0c45mKEh2IHHj[ZR6dGG2aX;uMUeyNlI3ODF4Nh?=
DU145M3f1UGtqdmG|ZTDBd5NigQ>?NWjBeYpZPSEQvF2=MnroNlQhcA>?NGPXW2lFVVORM{CxU2lvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCqaYP0c45mKEh|IHj5dIVz[WOndInsZZRqd25?MWWyNlI3ODF4Nh?=
786-0M33SO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1rRd|YvOiEQvF2=MWe3NkBpNFrGN3lFVVORMVrHTVUxRTNwMjFOwG0>NES0XJEzOjR|NU[2PS=>
A498MkHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVq2MlIh|ryPMofhO|IhcA>?MXvEUXNQM4nFXWdKPTB;MT62JO69VQ>?NIPKZYUzOjR|NU[2PS=>
A549/ATCCM4HQbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkPQOk4zKM7:TR?=MkfJO|IhcA>?MnTvSG1UVw>?MkP0S2k2OD1zLk[g{txONGXRdVkzOjR|NU[2PS=>
ACHNNGHRXm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUHpV4NXPi5{IN88US=>M1Tv[VczKGh?NFXNN4lFVVORNEXFPVBIUTVyPUGuN{DPxE1?MYKyNlQ{PTZ4OR?=
BT549NVzsPXVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXGyW3hzPi5{IN88US=>NIjVPVI4OiCqMVrEUXNQM1fRUGdKPTB;MT6zJO69VQ>?MWeyNlQ{PTZ4OR?=
EKVXNXvIOVlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV7lNVQ4Pi5{IN88US=>MoXiO|IhcA>?MYrEUXNQNWPK[ZFkT0l3ME2xMlMh|ryPNEjnW4QzOjR|NU[2PS=>
HCT15M4rHNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmnJOk4zKM7:TR?=MWi3NkBpNFzGdJNFVVORNUK0TmN3T0l3ME2yMlUh|ryPMVKyNlQ{PTZ4OR?=
HOP92M2qwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGXxW5c3NjJizszNNFjIT4Y4OiCqM37IfGROW09?MYTHTVUxRTRizszNNV3mbJFiOjJ2M{W2Olk>
IGROV1NYm5U3pLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mnr1Ok4zKM7:TR?=M{fpWVczKGh?M1;yN2ROW09?NESwN2lIUTVyPUGuN{DPxE1?MWOyNlQ{PTZ4OR?=
LOXIMVIM3i4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVXlSZFlPi5{IN88US=>M2\CTVczKGh?MkXwSG1UVw>?NH\TblNIUTVyPUGg{txONHyzU|YzOjR|NU[2PS=>
M14M2ru[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVK2MlIh|ryPNVfD[GJCPzJiaB?=NVnTSox2TE2VTx?=M3HZXmdKPTB;MT6zJO69VQ>?MWqyNlQ{PTZ4OR?=
MALME-3MMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkLvOk4zKM7:TR?=NXHnUXlRPzJiaB?=MYPEUXNQNYDPSJRUT0l3ME2wMlMzKM7:TR?=NH3NT5ozOjR|NU[2PS=>
MCF10AMkjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3rKWFYvOiEQvF2=MUG0PEBpNXmxfGdFTE2VTx?=MofXS2k2OD17Lk[g{txONXXjNYxjOjJ2M{W2Olk>
MDA-MB-435MlftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mkj3Ok4zKM7:TR?=M{jhUFczKGh?MV7EUXNQMXPHTVUxRTBwNTFOwG0>NFK2bJQzOjR|NU[2PS=>
MDA-MB-468MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXG2MlIh|ryPM{\m[lczKGh?MnfxSG1UVw>?NIizdplIUTVyPUCuOlMh|ryPMkjsNlI1OzV4Nkm=
MOLT4MmrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXm2MlIh|ryPM{n5eFczKGh?MnzRSG1UVw>?M2iwOmdKPTB;MD60JO69VQ>?MWOyNlQ{PTZ4OR?=
NCI-ADR-RESMl7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX:2MlIh|ryPMXK3NkBpNFjqNJRFVVORM4\CR2dKPTB;MD6xOkDPxE1?NULCc4RUOjJ2M{W2Olk>
NCI-H23NUTVS4l7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlvuOk4zKM7:TR?=MmTnO|IhcA>?MnjMSG1UVw>?MWnHTVUxRTFizszNMorINlI1OzV4Nkm=
NCI-H322MMYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmHNOk4zKM7:TR?=NVPhfYxVPzJiaB?=MYnEUXNQNIPHbmVIUTVyPUCuO|kh|ryPMVGyNlQ{PTZ4OR?=
NCI-H460MnvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV;oT5p3Pi5{IN88US=>M3ntXlczKGh?NF62eGJFVVORMXjHTVUxRTBwN{mg{txOMlriNlI1OzV4Nkm=
NCI-H522NXTQN29bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWC2MlIh|ryPMU[3NkBpNGi5[oJFVVORM{Gwc2dKPTB;MD61JO69VQ>?NEfSPIozOjR|NU[2PS=>
OVCAR3M4LyN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGmwZZA3NjJizszNMmnzO|IhcA>?NVfGN|huTE2VTx?=MXzHTVUxRTFwMzFOwG0>MXqyNlQ{PTZ4OR?=
OVCAR4Ml73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEf1bFY3NjJizszNMnLPO|IhcA>?Mo\XSG1UVw>?MmLnS2k2OD12IN88US=>M1jhNlIzPDN3Nk[5
OVCAR5MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYS0[pprPi5{IN88US=>MXG3NkBpNGT3OWNFVVORM1u4NGdKPTB;MD63PUDPxE1?M1XaclIzPDN3Nk[5
OVCAR8MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2XHXlYvOiEQvF2=NXfHfnlUPzJiaB?=MX\EUXNQNGH0N4xIUTVyPUCuOUDPxE1?NUH1TW9IOjJ2M{W2Olk>
RXF393MmH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUKwOG9ZPi5{IN88US=>M3S0[lczKGh?NHLiOnRFVVORMXvHTVUxRTFwMzFOwG0>NUDaVI16OjJ2M{W2Olk>
SF268NX3xdpJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mo\sOk4zKM7:TR?=MVq3NkBpNYT0c49FTE2VTx?=Mlj6S2k2OD1zLk[g{txOMUKyNlQ{PTZ4OR?=
SF295Ml7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MojlOk4zKM7:TR?=Mo\yO|IhcA>?MoWySG1UVw>?M3POZmdKPTB;MT62JO69VQ>?NYO4dGlpOjJ2M{W2Olk>
SF539NGjFWFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWC2MlIh|ryPNV\SWGlwPzJiaB?=NGTXc|NFVVORMl;CS2k2OD1{IN88US=>NXW5d45nOjJ2M{W2Olk>
SK-MEL-2NIfheJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mme0Ok4zKM7:TR?=NWfPbIp3PzJiaB?=MXLEUXNQM4ewRWdKPTB;MT6zJO69VQ>?NX[zdJR2OjJ2M{W2Olk>
SK-MEL-28NWnjcnpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVLDWVhwPi5{IN88US=>NGS3W484OiCqNUHxdXpKTE2VTx?=MVPHTVUxRTFizszNM{i3VlIzPDN3Nk[5
SK-MEL-5MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV62MlIh|ryPMmH0O|IhcA>?NWPacWQ2TE2VTx?=M37zU2dKPTB;MD62N{DPxE1?MVOyNlQ{PTZ4OR?=
SKOV3M{jzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFHscmc3NjJizszNM2j3cFczKGh?Moe5SG1UVw>?NHL6V2xIUTVyPUGg{txONV7KO4huOjJ2M{W2Olk>
SN12CNHvI[XpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEjrVnA3NjJizszNNHLN[pI4OiCqMmLwSG1UVw>?MW\HTVUxRTJizszNMViyNlQ{PTZ4OR?=
SNB19MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4T0eVYvOiEQvF2=M13vS|czKGh?NFnPZWxFVVORNV;TNWZET0l3ME2wMlY{KM7:TR?=NFvJb2QzOjR|NU[2PS=>
SNB75M37wNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHO5cI83NjJizszNNYnC[IlmPzJiaB?=MoLZSG1UVw>?MVvHTVUxRTBwN{mg{txOMYiyNlQ{PTZ4OR?=
SRMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX:2MlIh|ryPNVHJcoc2PzJiaB?=MVfEUXNQNHH3ZZhIUTVyPUCuOEDPxE1?MoX5NlI1OzV4Nkm=
T47DMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXq2MlIh|ryPM1XMV|czKGh?MWjEUXNQM37VS2dKPTB;MD61JO69VQ>?NFnIZXMzOjR|NU[2PS=>
TK10M3rRbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUC2MlIh|ryPNIfycGc4OiCqM3zVWGROW09?NFjtUYZIUTVyPUCuOlMh|ryPMoLlNlI1OzV4Nkm=
UACC257NX76dXNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4T6U|YvOiEQvF2=M1rFWlczKGh?Mn;ESG1UVw>?MkPKS2k2OD1yLkWg{txOM1TLXVIzPDN3Nk[5
UACC62M3HLSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHXMXpo3NjJizszNMlnyO|IhcA>?M{LtZ2ROW09?Ml3ZS2k2OD1yLkSg{txONEXRNVIzOjR|NU[2PS=>
UO31NV\YN5hJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHfNcGg3NjJizszNNIPrbmo4OiCqNF\lXXJFVVORM{D0dmdKPTB;MD61JO69VQ>?Mm\2NlI1OzV4Nkm=
Hep3BNXWxfld{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmOxOFghcA>?M4nYW2ROW09?MnXuS2k2OD1yLk[5JO69VQ>?MnTzNlI1Ozl6NkO=
BE(2)-CNGD6c3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXO3UIZmPzJiaB?=M2TCfGROW09?MluxTWM4OD1{IN88US=>NYjURYx[OjJ7M{KzNVY>
Bel7402MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUTkOnVPPzJiaB?=NVry[3FGTE2VTx?=M{flV2dKQTB;MUeg{txONX;VWmdtOjNyNkGzO|Y>
Bel7404NWnwNFFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3ztclczKGh?NXvQNHNpTE2VTx?=NEjVfIpIUTlyPUG4JO69VQ>?M{joVlI{ODZzM{e2
BGC823MkiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmTKO|IhcA>?NFmyOmJFVVORMlfiS2k6OD15LkWg{txOMkK0NlMxPjF|N{[=
MGC803NX60Nld5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4iyTFczKGh?NYrUVppETE2VTx?=MljuS2k6OD1zMD64JO69VQ>?NYn4U4xZOjNyNkGzO|Y>
SGC7901NGPle|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlTmO|IhcA>?MnfCSG1UVw>?NIXVfIxIUTlyPUmuOEDPxE1?MYqyN|A3OTN5Nh?=
SKHEP1MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFL0ZnA4OiCqM1T3R2ROW09?M2XldWdKQTB;MUeg{txOMl36NlMxPjF|N{[=
SMMC7721MknkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnPxO|IhcA>?NHri[|hFVVORMVHHTVkxRTJyIN88US=>M{PURlI{ODZzM{e2
NUGC3MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3r3TVExKM7:TR?=NW[2doJpT0l;Mj65OEDPxE1?NUXPSYdlOjNzNkOzN|I>
A2780 CisRNXvjPGNMU2mwYYPlJGF{e2G7MXWxPEBpNEXveldKdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR|UxKG:oIECuOFQh|ryPNFLmW3AzOzJ3Mk[wNy=>
CAL27 sensNYLITIFoU2mwYYPlJGF{e2G7MYWxPEBpNGXxXZRKdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR|UxKG:oIECuN|Yh|ryPM{fYN|I{OjV{NkCz
CAL27 CisRNVX0c246U2mwYYPlJGF{e2G7M3PnRlE5KGh?NF21TXhKdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR|UxKG:oIECuOlEh|ryPMUCyN|I2OjZyMx?=
KYSE-510 CisRNFTncnNMcW6jc3WgRZN{[Xl?Ml;oNVghcA>?NHyw[5ZKdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR|UxKG:oIECuOVkh|ryPM2XqfFI{OjV{NkCz
KYSE-510 sensNIPlO4RMcW6jc3WgRZN{[Xl?M2TnT|E5KGh?NIDzZpJKdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR|UxKG:oIECuO{DPxE1?MlLINlMzPTJ4MEO=
MDA-MB-231 sensMX7LbY5ie2ViQYPzZZk>M3XHXFE5KGh?M3;GcGlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD62NUDPxE1?MmnxNlMzPTJ4MEO=
MDA-MB-231 CisRMXXLbY5ie2ViQYPzZZk>NWXz[md3OThiaB?=MojmTY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLk[xJO69VQ>?Mn[xNlMzPTJ4MEO=
ES2MmTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoP1OFghcA>?M4[1U2ROW09?MWLJR|UxRTF{Lkeg{txONXTC[FRlOjN2OUO0OFk>
MDA-MB-231NVjUOI1[U2mwYYPlJGF{e2G7NWPh[41JOTBizszNMV6zNEBucW5?MVjEUXNQM2f1TGlvcGmkaYTpc44hd2ZiSFTBR|JiNXLSUHNmOjN2OUO0OFk>
MDA-MB-231NEHNbJhMcW6jc3WgRZN{[Xl?M4rGeFEh|ryPNGroW2ozPCCqNWnFWpRJTE2VTx?=MUXJcohq[mm2aX;uJI9nKEiGQVO2JIF{e2W|c3XkJIF{KGGlZYT5cIF1cW:wIHzleoVteyCxZjD0eYJ2dGmwM3T4WlI{PDl|NES5
HS68NVTjUXVWS3m2b4TvfIlkKEG|c3H5M1L1XFExKM7:TR?=MUK3NkBpMWTEUXNQNVnPO5k1UUN3ME20MlYh|ryPMWGyN|U4ODV2Mh?=
MEFMUfDfZRwfG:6aXOgRZN{[Xl?MkHYNVAh|ryPMWO3NkBpMkHBSG1UVw>?M17Pd2lEPTB;ND60JO69VQ>?M2LOWFI{PTdyNUSy
BGC823M33SVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFLTTZlFVVORMU\HTVUxRTNwMEmg{txONXzpbWlZOjN4MEG3NFY>
High5MUHLbY5ie2ViQYPzZZk>NYnBeZRjOjRiaB?=M2PzdGlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiSFTBR|Yhf2m2aDDJR|UxKG:oIECuNFkh|ryPM17xUFI{PjB{NUKz
High5M3HPSGtqdmG|ZTDBd5NigQ>?NXL4XW5xOjRiaB?=MUPJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KEiGQVOxJJdqfGhiSVO1NEBw\iByLkGyJO69VQ>?MW[yN|YxOjV{Mx?=
High5MV;LbY5ie2ViQYPzZZk>Mni5NlQhcA>?MX\Jcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KEiGQVOzJJdqfGhiSVO1NEBw\iByLkG3JO69VQ>?MmrjNlM3ODJ3MkO=
A549NXXUSHFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoXDSG1UVw>?NFi1T2lKSzVyPUGuNFc6KM7:TR?=MojhNlM3PDR{MUC=
HCT116M4PPfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NETSdopFVVORMmHQTWM2OD1yLke1O{DPxE1?NVnaVlF[OjN4NESyNVA>
K562NWrZTGxsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYDtW2h{TE2VTx?=NV;ob|kzUUN3ME2wMlY1PSEQvF2=MoLNNlM3PDR{MUC=
GBC-SDMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnLIOUDPxE1?NF:zeIs4OiCqNEXaTXZFVVORNX\sNYozUUN3ME2xOE45KM7:TR?=M1;BRlI{PzB5Mk[w
HGC27M4P4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2fuNlUh|ryPMVS3NkBpNIH2PZlFVVORM{nF[2lEPTB;NT60JO69VQ>?MXWyN|cxPzJ4MB?=
HL60MW\LbY5ie2ViQYPzZZk>M2PiflUh|ryPMUGyOEBpM{jUXGROW09?Mke0TY5pcWKrdHnvckBw\iCKRFHDNIC5TVkzOzdyN{K2NC=>
VeroM17VbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2LOSVczKGh?MVHEUXNQMkjYTWM2OD1yLkmg{txOMWKyN|c5PjR3Mh?=
NCI60MV\DfZRwfG:6aXOgRZN{[Xl?M{i1blQ5KGh?NWPofplPTE2VTx?=MXHHTV0xNjV|IN88US=>M2TIdlI1ODF3M{K3
SW620NXHmXnBNS3m2b4TvfIlkKEG|c3H5MYq0PEBpMYHEUXNQMXHHTV0xNjV2IN88US=>MWCyOFAyPTN{Nx?=
U251MV7DfZRwfG:6aXOgRZN{[Xl?NXHLPFAyPDhiaB?=M173UGROW09?M{PEbWdKRTFwNUOg{txONVjN[G5oOjRyMUWzNlc>
KM12MUPDfZRwfG:6aXOgRZN{[Xl?MV20PEBpNWPJNHBzTE2VTx?=MV;HTV0yNjh6IN88US=>M17kcVI1ODF3M{K3
Hs578TNHTxUGdEgXSxdH;4bYMhSXO|YYm=M1\vR|Q5KGh?MVjEUXNQM2KxcWdKRTRwOEOg{txOMkXUNlQxOTV|Mke=
MDA-MB-231NHv2SoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1zBcVQ5KGh?MUXJR|UxRTBwMU[g{txOMUOyOFA6PTBzNh?=
MCF7NHv6e4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUC0PEBpMnv2S2k:OC52NTFOwG0>NXTsTXB5OjRzMUm1OVU>
MDA-MB-435NVyzcJNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWH4WnJlPDhiaB?=MnmxS2k:OC56ODFOwG0>NETLXJczPDFzOUW1OS=>
AsPC1NYLZVZNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFyyfIU{OCEQvF2=MoruOFghcA>?NHPKOpRFVVORNXXoWZBJUUN3ME2zMlY3KM7:TR?=M3ziZVI1OTh3M{e4
Jurkat E6.1MnjCT4lv[XOnIFHzd4F6MljCNkBpMlf5SG1UVw>?MXPJcohq[mm2aX;uJI9nKEiGQVO0JJdqfGhiSVO1NEBw\iByLkC0JO69VQ>?MUOyOFI3OTh4Mh?=
KG1NFPSXXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYK0PEBpNVPBemVsUUN3ME2xMlE2KM7:TR?=MlrPNlQ2OjVyMEO=
HELMn3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX[0PEBpMkHhSG1UVw>?MWrJR|UxRTBwNEmg{txONWrzRodlOjR4OUSwOVU>
HSC3Ml7nR5l1d3SxeHnjJGF{e2G7M2DYWVEzKGh?MYDEUXNQNWTXWGNzUUN3ME2wMlcyKM7:TR?=M1Wxb|I1PzZ4NU[w
HT-29NF3LTYNEgXSxdH;4bYMhSXO|YYm=M3nUcFEzKGh?NFrQbmJFVVORMV;JR|UxRTBwN{Kg{txONVjYemdXOjR5Nk[1OlA>
KBM37h[2N6fG:2b4jpZ{BCe3OjeR?=MVWxNkBpM2HzO2ROW09?NV\pZ5RNUUN3ME2wMlc2KM7:TR?=MXSyOFc3PjV4MB?=
H460MoXiR5l1d3SxeHnjJGF{e2G7MYmxNkBpMVPEUXNQNELVVodKSzVyPUCuPFIh|ryPM4Xu[FI1PzZ4NU[w
MONE1MojrR5l1d3SxeHnjJGF{e2G7NUC1bIY1OTJiaB?=MVvEUXNQMn3zTWM2OD1zLkG4JO69VQ>?NYjMfY1YOjR5Nk[1OlA>
MKN45M3zZWGN6fG:2b4jpZ{BCe3OjeR?=NUHvNmtqOTJiaB?=NFy0RWFFVVORNGL3RZJKSzVyPUGuNlUh|ryPMUmyOFc3PjV4MB?=
TSGHNWPZV|RFS3m2b4TvfIlkKEG|c3H5M2jUU|EzKGh?MYTEUXNQNWXMWWZ5UUN3ME2yMlA6KM7:TR?=MVuyOFc3PjV4MB?=
HL60MnXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYnxXWVYPzJiaB?=M37wZmROW09?Mnz6S2k2OD1yLkmzJO69VQ>?MVeyOFkxODVyMB?=
HEK293NWr4[lN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3\2eVczKGh?NHvjdJBFVVORMmj1S2k2OD1zMzFOwG0>MVyyOFkxODVyMB?=
JurkatNUnZR3hHS3m2b4TvfIlkKEG|c3H5Ml7uNVAxKM7:TR?=NWrvdJF6PzJiaB?=NIrldppIUTVyPUCuPUDPxE1?NEXLfZQzPDlyMEe0Ny=>
GM15850M1m0PGtqdmG|ZTDBd5NigQ>?MoLrNk42KM7:TR?=M{mycVk3KGh?M4W5dGROW09?NXPBTWxX\G:nczDuc5QhcW6qaXLpeEBJTEGFIHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGirc4TvcoUhUDNibInzbY5mKDF2IHHj[ZR6dGG2aX;uJI9nKE[[TjDn[Y5mMXOxOlkzOTN4Nx?=
GM15850M{WwXWtqdmG|ZTDBd5NigQ>?MXiyMlUh|ryPMYC5OkBpNF\md3dFVVORM3XEbYRw\XNibn;0JIlvcGmkaYSgTGRCSyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBpcXO2b37lJGg1KGy7c3nu[UA2KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7lMV2xOlkzOTN4Nx?=
GM15850M{LPbGtqdmG|ZTDBd5NigQ>?NX6yOJJDOi53IN88US=>MnX4PVYhcA>?NVXDOINMTE2VTx?=MV;kc4V{KG6xdDDpcohq[mm2IFjERWMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgNVIh[WOndInsZZRqd25ib3[gSnhPKGenbnW=MYexOlkzOTN4Nx?=
GM15850NYT0[5JzU2mwYYPlJGF{e2G7NFv0dpQzNjVizszNMm\MPVYhcA>?NIqxSpFFVVORMon3[I9meyCwb4SgbY5pcWKrdDDISGFEKGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMhdHm|aX7lJFkh[WOndInsZZRqd25ib3[gSnhPKGenbnW=NHrGeXgyPjl{MUO2Oy=>
GM15850NXnGOIFjU2mwYYPlJGF{e2G7MmnSNk42KM7:TR?=M{T1[|k3KGh?NGi0TVFFVVORMkPN[I9meyCwb4SgbY5pcWKrdDDISGFEKGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm|aX7lJFgh[WOndInsZZRqd25ib3[gSnhPKGenbnW=MmTJNVY6OjF|Nke=
GM15850MYrLbY5ie2ViQYPzZZk>NIjFRWUzNjVizszNM{DQdFk3KGh?MYnEUXNQMUXkc4V{KG6xdDDpcohq[mm2IFjERWMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgNVYh[WOndInsZZRqd25ib3[gSnhPKGenbnW=MYmxOlkzOTN4Nx?=
GM15850M37VTWZ2dmO2aX;uJGF{e2G7MkHmOUDPxE1?M4GzWFEzKGh?NWH4blB[TE2VTx?=NVfaZphNcGG|IH7vJIVn\mWldDDvckBHYE5ibWLORUBmgHC{ZYPzbY9vM1fw[VE3QTJzM{[3
U937MUjLbY5ie2ViQYPzZZk>NFzXeYE2KM7:TR?=Mk\4NlQhcA>?NFTDc5BFVVORNH[0VYtp[XNibn:g[YZn\WO2IH;uJIFteGijIIT1ZpVtcW5iYXPleJlt[XSrb36=MYKxO|Q1Pzd3MB?=
U937NXv2bmhtU2mwYYPlJGF{e2G7MV:xJO69VQ>?NVTuV4VrOjRiaB?=NIHvbG9FVVORNHzD[XNp[XNibn:g[YZn\WO2IH;uJIFteGijIIT1ZpVtcW5iYXPleJlt[XSrb36=NUnvV2ZMOTd2NEe3OVA>
PANC1NHvVNJBHfW6ldHnvckBCe3OjeR?=MofSNUDPxE1?MUiyOEBpMoW1[I9meyCwb4SgbY5kemWjc3WgbY4heDJ5a3nwNUBo\W6nIHX4dJJme3Orb36=NY\Re2dvOTd3OEi3OFQ>
PANC1MorZSpVv[3Srb36gRZN{[Xl?NFLldHgyKM7:TR?=MmPNOFghKGh?Ml7k[I9meyCwb4SgbY5kemWjc3WgbY4heDJ5a3nwNUBo\W6nIHX4dJJme3Orb36=MV[xO|U5QDd2NB?=
Caco-2MUHGeY5kfGmxbjDBd5NigQ>?MXO1JO69VQ>?NIDxfYczPCCqNH6zTGNFVVORM3\0UoRw\XNibn;0JIlv\HWlZTDQNlFYSUZzIHflcoUh\XiycnXzd4lwdg>?MoOxNlAyPDN6NEC=
SCC4NHnx[YJHfW6ldHnvckBCe3OjeR?=MofzNUDPxE1?NFftRWoyOCCvaX6=MUPEUXNQNH7ke2Vp[XNibn:gZYdwdmm|dDDhZ5Rqfmm2eTDheEBXTFJiYYPz[ZN{\WRiYYOgbY5lfWO2aX;uJI9nKEO\UEK0JIdmdmViZYjwdoV{e2mxbh?=NXnLUm04OjB2NUKyNlU>
A549NVq4NJVoTnWwY4Tpc44hSXO|YYm=NEPLd5I2KM7:TR?=NVW1SVdVOyCqMYXEUXNQMofL[I9meyCwb4SgbY5lfWOnIHH1eI9xcGGpeTDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCOQ{PJTS=>NH;peZMzODh3NUKwPC=>
HCT116NVvwTYdSU2mwYYPlJGF{e2G7MnfRNE4{KM7:TR?=MVOzNEBpMXPEUXNQNXviXG4{\G:nczDuc5QhcW6qaXLpeEBJTEGFMTDhd5Nme3OnZDDhd{BqdmS3Y4Tpc44hd2ZiaHnzeI9v\SCKM1u5JIFk\XS7bHH0bY9vMX2yNVA5ODZ2Nx?=
HepG2M3K5fmZ2dmO2aX;uJGF{e2G7MYqxNEDPxE1?NYL2V|ZHOjRiaB?=MVjEUXNQM1PsSIRw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYOgZZN{\XO|ZXSgZZMhcHmyZYLhZ4V1gWyjdHnvckBw\iCyNUO=MUCyNVU1QDV6Mh?=
GM11272MVjGeY5kfGmxbjDBd5NigQ>?Ml3RNE4yKM7:TR?=NWfOOYdwPzJiaB?=M1HXZmROW09?M3\ufYRw\XNibn;0JJJm[WO2aY\heIUhVWWFcEKgcZV1[W62IHX4dJJme3Orb36=NE[2c28zOTh2MEexOi=>
MDA-MB-231MXTLbY5ie2ViQYPzZZk>NIrWb|YyOCEQvF2=NYrPSYFHPSCvaX6=NV;oVGJWTE2VTx?=MX3kc4V{KG6xdDDpcohq[mm2IFjERWMz[Q>?NH7CVJYzOzR7M{S0PS=>
MDA-MB-231NF;HUYdMcW6jc3WgRZN{[Xl?NW\yS2w4OSEQvF2=NFfKboYzPCCqNEDKeIRFVVORM1XzVoRw\XNibn;0JIlvcGmkaYSgTGRCSzZiYYPz[ZN{\WRiYYOgZYNmfHmuYYTpc44hdGW4ZXzzJI9nKHS3YoXsbY4>NEWySW8zOzR7M{S0PS=>
K562M2HSOWtqdmG|ZTDBd5NigQ>?MoPJ[I9meyCwb4SgbY5pcWKrdDDISGFEMojTNlM2QTFzMUG=
JurkatM{[4dmN6fG:2b4jpZ{BCe3OjeR?=NGLr[JEzOCEQvF2=MWK3NkBpMVTEUXNQM1LX[I5wKGO7dH;0c5hq[2m2eTDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvci=>NFq0bXEzPDNyNEO0PC=>
HCT116Ml:yRZBweHSxc3nzJGF{e2G7NUfUWGUyOyEQvF2=M1rjNlI1KGh?Ml\DSG1UVw>?NUn4O|Q4\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDwOVMheHKxdHXpckBt\X[nbB?=NWX2fmRROjR5Nk[1OlA>
KASUMI-1NVy2WpRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2PNSmlEPTB;OUmuNVchdk1?MUHTRW5ITVJ?
KARPAS-45M1XUTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYDJR|UxRTF5Mz64PUBvVQ>?MkHkV2FPT0WU
BHT-101MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEDa[nlKSzVyPUK0OE4yQCCwTR?=MlnUV2FPT0WU
H9M3z3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXHJR|UxRTJ3NT6wOEBvVQ>?MnznV2FPT0WU
PA-1NHjTRoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWjqWFlOUUN3ME2yPFYvOjZibl2=M2HiVXNCVkeHUh?=
NEC8M{TY[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYLJR|UxRTJ6OT6zPEBvVQ>?MnTSV2FPT0WU
MHH-PREB-1MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NInhV4VKSzVyPUK5OE42OyCwTR?=NXnUTotHW0GQR1XS
NB7MlP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MULJR|UxRTN2NT63OEBvVQ>?NV\GWINVW0GQR1XS
A3-KAWMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoL3TWM2OD12MECuOVkhdk1?M3W5eXNCVkeHUh?=
NB69M17IZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWfjO|ZIUUN3ME20NVEvPzFibl2=NILC[ZZUSU6JRWK=
EoL-1-cellMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXrJR|UxRTR3NEK1JI5OM{n5e3NCVkeHUh?=
CHP-212NVHUZ3BWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnLGTWM2OD12NUeuOVMhdk1?NHTGPZdUSU6JRWK=
C2BBe1MnHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{[wO2lEPTB;NEeyMlE6KG6PMmfsV2FPT0WU
697MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIjzOGlKSzVyPUS3N{41OSCwTR?=MVHTRW5ITVJ?
BCPAPM2DDRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEHEe5VKSzVyPUWwNU41OiCwTR?=MmnVV2FPT0WU
L-363MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV7JR|UxRTVyMz6xJI5OMlHEV2FPT0WU
ES8NGn2fnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVrJR|UxRTV{Mz61N{BvVQ>?NWXzPXMyW0GQR1XS
BE-13NFzQTZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mo\BTWM2OD13Mk[uPVYhdk1?NEK3bYJUSU6JRWK=
CTB-1M4HadGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlS4TWM2OD13M{euPVIhdk1?NX[3b2V[W0GQR1XS
HD-MY-ZMnTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWrsT4RQUUN3ME21N|gvOTNibl2=NXO4UnpRW0GQR1XS
NKM-1M4jvNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYXJR|UxRTV2ND6yO{BvVQ>?NUH0WYd[W0GQR1XS
NCI-H720NYrzVYtET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoHHTWM2OD13NkCuNVghdk1?M3\pTHNCVkeHUh?=
KY821Moq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVf5c5dTUUN3ME21OlMvOjVibl2=M{\0d3NCVkeHUh?=
OVCAR-5M2Xabmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEG5eHZKSzVyPUW3Ok4yOSCwTR?=MkjpV2FPT0WU
CTV-1Mlz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlzaTWM2OD13OEGuOVYhdk1?MYrTRW5ITVJ?
P12-ICHIKAWANGf3botIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4fMOmlEPTB;NUm2MlUyKG6PMl;XV2FPT0WU
DBMkjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHHrUnZKSzVyPUW5PE42PyCwTR?=NWPre2EyW0GQR1XS
CHL-1MkHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHfoUohKSzVyPU[0Nk4xQCCwTR?=MofCV2FPT0WU
A4-FukNYrjTZhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlHMTWM2OD14NESuPVEhdk1?NFjlPZhUSU6JRWK=
MV-4-11MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYTKZWlOUUN3ME22OVkvOSCwTR?=MUTTRW5ITVJ?
RPMI-8226M3jHPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVTFbIVSUUN3ME22O|gvOThibl2=NIW4b41USU6JRWK=
NB14Ml\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYi5bpk3UUN3ME22PVYvQTVibl2=MUnTRW5ITVJ?
DOHH-2NHPHfGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4\tW2lEPTB;N{C2MlY5KG6PMV7TRW5ITVJ?
D-423MGNYnkd2pvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFvDWYVKSzVyPUewOk45QSCwTR?=M4\scHNCVkeHUh?=
D-283MEDNIXGXpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVr6dnU1UUN3ME23NVQvOTRibl2=MlzUV2FPT0WU
ES1Ml7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVjJR|UxRTd{ND60JI5ONV;WTnE{W0GQR1XS
GOTOM3vFRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEjuSYNKSzVyPUeyPU4yOiCwTR?=NGG2dJdUSU6JRWK=
NCI-H209M3npdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI[4doJKSzVyPUeyPU46KG6PM4qxbHNCVkeHUh?=
MOLT-13M1TUOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWe2XVF7UUN3ME23N|gvQThibl2=MnPsV2FPT0WU
ATN-1NEXt[nZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHjPdVdKSzVyPUe0NE4zQCCwTR?=NFPJVHJUSU6JRWK=
DU-4475M{\KU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1HSXGlEPTB;N{WxMlkyKG6PNUm0W25WW0GQR1XS
NB10MoXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVz0[HM1UUN3ME23OVEvQTJibl2=NW\qTWJDW0GQR1XS
KG-1M4jkWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml;GTWM2OD15N{WuOFUhdk1?NFnwUo5USU6JRWK=
MOLT-4NV7KfJZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmrnTWM2OD15OEeuOFYhdk1?MlnYV2FPT0WU
TE-1NWLETpFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M13PNWlEPTB;N{mxMlEhdk1?Ml7zV2FPT0WU
SBC-1NXjsb|U{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTd7Mz64OEBvVQ>?M4XJRnNCVkeHUh?=
HELNV:1dlFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmT4TWM2OD16ME[uNFghdk1?NVTQZ5hOW0GQR1XS
SK-MEL-2MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlXpTWM2OD16MEmuOFQhdk1?NFXLOGNUSU6JRWK=
KU812M3XVOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYXJR|UxRThzMz6xJI5ONHTzOnBUSU6JRWK=
RPMI-8866MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1rNZmlEPTB;OEGzMlY4KG6PNIqxWHBUSU6JRWK=
ALL-POM{PORmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUP4fYNmUUN3ME24NVQvPjZibl2=NHLVUpdUSU6JRWK=
LU-139NYPOU3dDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVfJR|UxRTh{Mj64OkBvVQ>?MYTTRW5ITVJ?
RS4-11NYTnPJBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVzJR|UxRTh|Mj60OUBvVQ>?NGrOVVZUSU6JRWK=
EW-18NFTnTW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkPITWM2OD16M{KuPVYhdk1?Ml7jV2FPT0WU
P30-OHKNEj0cWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRTh|NT63JI5OMWfTRW5ITVJ?
D-566MGNWHTU3ZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MljnTWM2OD16M{iuOlIhdk1?MlTCV2FPT0WU
HSC-4M{jXVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1PnfWlEPTB;OES2MlUyKG6PNYm1RXhGW0GQR1XS
QIMR-WILNGjjOoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlfITWM2OD16NkKuNFMhdk1?MUfTRW5ITVJ?
SW954NV\NdZl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX;JR|UxRTh4Mz6xOkBvVQ>?MoSzV2FPT0WU
HGC-27M334cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH3kdVNKSzVyPUi3Nk4{PCCwTR?=MVnTRW5ITVJ?
HHNX;he4pwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn;iTWM2OD16OUSuNVIhdk1?NIGwUnlUSU6JRWK=
KE-37MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml\NTWM2OD16OUSuOlIhdk1?NUHn[2U{W0GQR1XS
SK-N-DZM1W3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRTlyMD60N{BvVQ>?MVzTRW5ITVJ?
J-RT3-T3-5MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmHKTWM2OD17MUCuOFkhdk1?M1jMTHNCVkeHUh?=
A427M1\ROWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYfwV2NrUUN3ME25NlAvQDRibl2=Mn\NV2FPT0WU
ECC10M2DFVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVvYRpk2UUN3ME25OFUvQDdibl2=NXHWWIU5W0GQR1XS
EW-1NEXjZmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX3JR|UxRTl2Nz6yOkBvVQ>?MnPNV2FPT0WU
MIA-PaCa-2MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV3JR|UxRTl2OT6xNkBvVQ>?MlrOV2FPT0WU
HCC2218MnGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIfuSINKSzVyPUm1PE41QCCwTR?=NUfiTopNW0GQR1XS
HAL-01NFTtbHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{PnOmlEPTB;OU[4MlA1KG6PMYPTRW5ITVJ?
RDMl\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mkn3TWM2OD17N{SuOFUhdk1?MkfrV2FPT0WU
SK-N-ASMnfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M163[2lEPTB;OUi4MlEhdk1?M4m3NHNCVkeHUh?=
ML-2NFXJVYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkDGTWM2OD1zLkCwOFA4KM7:TR?=NF7nNXlUSU6JRWK=
MEL-HONX34RVI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{nnVmlEPTB;MT6wNFU5OiEQvF2=NVz1cIU2W0GQR1XS
MS-1NXz3fno3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4LEdGlEPTB;MT6wNFYyPyEQvF2=NHX0OXpUSU6JRWK=
NCI-SNU-1M4PJR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXrJR|UxRTFwMEKzN|Eh|ryPMlXlV2FPT0WU
8505CNFzpfnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF3oR5dKSzVyPUGuNFI{OzFizszNNF7QdFRUSU6JRWK=
MN-60MlvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnXxTWM2OD1zLkCyOlgh|ryPM365bXNCVkeHUh?=
SASMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVHJR|UxRTFwMESwPFEh|ryPNGT6Om9USU6JRWK=
EFM-19NWHmPYxXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHLYVIFKSzVyPUGuNFQ5PzlizszNMmTmV2FPT0WU
Ca9-22M2SyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1\QPWlEPTB;MT6wOVExPyEQvF2=M{D4RXNCVkeHUh?=
NBsusSRMXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUDwbmNXUUN3ME2xMlA2OTZ4IN88US=>M1vjfXNCVkeHUh?=
NB13MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFvye4ZKSzVyPUGuNFU2ODFizszNMULTRW5ITVJ?
SF295MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYrJR|UxRTFwME[2NlQh|ryPM2H0THNCVkeHUh?=
U-2-OSNXftWG5[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGX1THRKSzVyPUGuNFc6OTFizszNMYfTRW5ITVJ?
NCI-H526NXXOSWVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4mzb2lEPTB;MT6wPFI6OSEQvF2=NGLIdWZUSU6JRWK=
KMOE-2MlWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NULqU5JWUUN3ME2xMlA6PDJ{IN88US=>NUfLcoZ[W0GQR1XS
RCM-1M1LjfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3i4UmlEPTB;MT6xNlExOiEQvF2=MVXTRW5ITVJ?
MC116NGSyZphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEPvUVBKSzVyPUGuNVM3OjFizszNNHH6dWxUSU6JRWK=
NCI-H1092MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlrUTWM2OD1zLkG1OFA3KM7:TR?=M2jxTnNCVkeHUh?=
EW-3NUfybYZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWPJR|UxRTFwMUeyNVIh|ryPM2fLV3NCVkeHUh?=
HCT-116Mmi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGrNbpVKSzVyPUGuNVc4PSEQvF2=MXnTRW5ITVJ?
MC-IXCMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX7JR|UxRTFwMUe4PFEh|ryPM{fnWHNCVkeHUh?=
LB1047-RCCMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXjJR|UxRTFwMUizNVIh|ryPMUfTRW5ITVJ?
VM-CUB-1Mn7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1zDdmlEPTB;MT6xPVExQCEQvF2=MUnTRW5ITVJ?
NB5M3ixdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{nVbWlEPTB;MT6xPVg2PiEQvF2=M4\lXnNCVkeHUh?=
SKG-IIIaM1L5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkDrTWM2OD1zLkKzOFY1KM7:TR?=M4DUbXNCVkeHUh?=
HO-1-N-1Mmi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUnJR|UxRTFwMkO4N|Uh|ryPMVTTRW5ITVJ?
EFO-27NH;qUVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF3BVoVKSzVyPUGuNlUxPDNizszNNG\MWVBUSU6JRWK=
MHH-NB-11M3XadGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NW\hcJB3UUN3ME2xMlI5OzJ7IN88US=>NGfCN3VUSU6JRWK=
SW620MnTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFLmTXBKSzVyPUGuNlkxOThizszNNFL5WXNUSU6JRWK=
MOLT-16MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEDPWHJKSzVyPUGuNlk4QTdizszNM4P4N3NCVkeHUh?=
NTERA-S-cl-D1NXzEXGMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWS5c2pUUUN3ME2xMlMyPzZzIN88US=>MVnTRW5ITVJ?
VA-ES-BJNWjnZWRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYPJR|UxRTFwM{K0O|ch|ryPMnLCV2FPT0WU
HCC1419NHK0Z4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVv0coR2UUN3ME2xMlM1ODJ5IN88US=>NIG2O4NUSU6JRWK=
NCI-H69NUn0[FFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV\uW4dQUUN3ME2xMlM1OTF{IN88US=>NF;WXYRUSU6JRWK=
DELNETDVlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2LuTmlEPTB;MT6zOVE3OiEQvF2=M2LkVXNCVkeHUh?=
LXF-289MoX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUPQNm9sUUN3ME2xMlM2OjRizszNNGj4OYJUSU6JRWK=
EW-11MoXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV:4SW5OUUN3ME2xMlM3ODJ4IN88US=>MYTTRW5ITVJ?
KP-4NXTydpR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXntWXNlUUN3ME2xMlM4ODh3IN88US=>NUTkPYRLW0GQR1XS
NOS-1NUfPeY45T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmHPTWM2OD1zLkSxNVk1KM7:TR?=NUDVVZA6W0GQR1XS
SK-NEP-1M1LJVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUHJR|UxRTFwNEG2PVMh|ryPNXXkelBlW0GQR1XS
LAMA-84NIfYSWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4W0NWlEPTB;MT60N|k1PSEQvF2=M33UfXNCVkeHUh?=
ES5NV3VNmRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWnRdpo2UUN3ME2xMlQ1OyEQvF2=NVvlPYRUW0GQR1XS
HuO9M3rnVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV;nUVdmUUN3ME2xMlQ2OzZ{IN88US=>MUfTRW5ITVJ?
COLO-684MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXXJR|UxRTFwNE[xNVgh|ryPNIXaRnZUSU6JRWK=
EW-24MkDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF[1VVFKSzVyPUGuOFY2OzFizszNMmjlV2FPT0WU
BV-173MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUPtPXhqUUN3ME2xMlQ4OjlzIN88US=>NVrzW|FVW0GQR1XS
NCI-H1770NXHZ[G5wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlTvTWM2OD1zLkS4OVM3KM7:TR?=M4W3cXNCVkeHUh?=
HuP-T4NHy2SGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYK2eItzUUN3ME2xMlQ6OyEQvF2=NI\GbmVUSU6JRWK=
TYK-nuNFOzUoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3TCZ2lEPTB;MT60PVg2OSEQvF2=MkntV2FPT0WU
YH-13MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1m1[mlEPTB;MT60PVg6PCEQvF2=NUPNZ5dkW0GQR1XS
H4NFrSRo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYPJR|UxRTFwNUC5NVIh|ryPNWP3UJZ1W0GQR1XS
OVCAR-8MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MW\JR|UxRTFwNUS0O|ch|ryPMkf5V2FPT0WU
NCI-H23NYr2TYFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkLBTWM2OD1zLkW0OlQ2KM7:TR?=NGfKW2hUSU6JRWK=
ES7MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV7JR|UxRTFwNUS3O|Mh|ryPNI\OOGdUSU6JRWK=
COR-L88NI\O[2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXfPXpFwUUN3ME2xMlU3PDJ2IN88US=>MXfTRW5ITVJ?
TI-73NYHu[ZdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWPLeodIUUN3ME2xMlU6ODZizszNMnLRV2FPT0WU
RT-112NWLMd5F{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUPPRWRKUUN3ME2xMlU6Ojh2IN88US=>MYTTRW5ITVJ?
HuO-3N1MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{fpeWlEPTB;MT61PVM5PSEQvF2=NV\ZNHFUW0GQR1XS
HC-1MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW\QS|diUUN3ME2xMlU6QDZ4IN88US=>M{CwcHNCVkeHUh?=
HT55NHnmVGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIDqTldKSzVyPUGuOlUyOzFizszNNFnXZ45USU6JRWK=
IA-LMNXPhcWRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M17kOmlEPTB;MT62PVI4QCEQvF2=MmHQV2FPT0WU
EM-2M1PyfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFHjZ5hKSzVyPUGuO|AxOTRizszNMkD1V2FPT0WU
MHH-ES-1M2TRNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1v0bGlEPTB;MT63NFQ{PSEQvF2=M4fpXHNCVkeHUh?=
CAL-27MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2HvU2lEPTB;MT63NFYzOSEQvF2=NEnhN4JUSU6JRWK=
COLO-800MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NI[0UYlKSzVyPUGuO|EyPzlizszNNEfxW41USU6JRWK=
HCE-TMkmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXnJR|UxRTFwN{G1JO69VQ>?MoLoV2FPT0WU
CAMA-1NUjnVpc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1HHNmlEPTB;MT63NVk4OSEQvF2=MlnmV2FPT0WU
LOXIMVIMYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV\JR|UxRTFwN{KxNUDPxE1?NYPGZpFsW0GQR1XS
NH-12M1;DNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV\JR|UxRTFwN{K2PVEh|ryPMnn2V2FPT0WU
TCCSUPMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYfPOGlsUUN3ME2xMlczQDJ7IN88US=>NWeybmJUW0GQR1XS
MDA-MB-361NYrNPYlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIX0PWRKSzVyPUGuO|MyPTdizszNMVTTRW5ITVJ?
EW-16M3rZe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn;KTWM2OD1zLke0NVA4KM7:TR?=NXvkW|lvW0GQR1XS
SNU-423NWTjVppJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEfHOolKSzVyPUGuO|U5OjdizszNNVH5fGcxW0GQR1XS
DaoyMYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn7ETWM2OD1zLke2N|E6KM7:TR?=NHGxdItUSU6JRWK=
ES4NUHvWWc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVnJR|UxRTFwN{i3OFEh|ryPM{PadXNCVkeHUh?=
PFSK-1MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHrsN|hKSzVyPUGuPFA{PyEQvF2=NVHZVGRHW0GQR1XS
ES3Mlf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{DzcmlEPTB;MT64NlY5OSEQvF2=M3L0R3NCVkeHUh?=
ONS-76Mkf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUTKTFR7UUN3ME2xMlgzQDl5IN88US=>MV3TRW5ITVJ?
JVM-3NF7GNm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUS2W3ZkUUN3ME2xMlg2PDVzIN88US=>NUXpb3ZkW0GQR1XS
OS-RC-2NV\6S5hbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWPXOZBEUUN3ME2xMlg4OTVzIN88US=>NUPEXmNxW0GQR1XS
COLO-320-HSRNHzXRZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU\4U2hJUUN3ME2xMlg5OTl5IN88US=>MorYV2FPT0WU
HNMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXrJR|UxRTFwOEi3NlUh|ryPNXrSU4RPW0GQR1XS
HTMUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF7X[llKSzVyPUGuPFg6PDdizszNMULTRW5ITVJ?
LoVoMXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFLqemFKSzVyPUGuPFk5OSEQvF2=MUTTRW5ITVJ?
CGTH-W-1NEnBXYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFvtWmFKSzVyPUGuPFk6PDZizszNNEK5[WRUSU6JRWK=
NB6MnL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn\vTWM2OD1zLkmxNlk5KM7:TR?=MWjTRW5ITVJ?
EW-22NWPmSYo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV7JR|UxRTFwOUK4PFch|ryPMWnTRW5ITVJ?
ES6M33hNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkC0TWM2OD1zLkmzOlMyKM7:TR?=MXjTRW5ITVJ?
SCC-15MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4XWTmlEPTB;MT65N|gyQSEQvF2=NYj2OYFrW0GQR1XS
HL-60MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{LiXWlEPTB;MT65N|kxOiEQvF2=NIjDUmlUSU6JRWK=
human HOP-92MnL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYrJR|UxRTFwOUSwOlUh|ryPNHTHSWdUSU6JRWK=
SW626MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVLJR|UxRTFwOUS4PVkh|ryPMkfZV2FPT0WU
HEC-1NXPYPWRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXqzR2E2UUN3ME2xMlk2OzZizszNNG\SVmxUSU6JRWK=
LB2241-RCCMojKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MW\JR|UxRTFwOUiyN|Eh|ryPNXHiPYtvW0GQR1XS
Ramos-2G6-4C10NIfGXoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUHWVnZTUUN3ME2xMlk6PDl|IN88US=>NITofIdUSU6JRWK=
A101DMnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEHmfldKSzVyPUKuNlA{ODNizszNNXzTd3J1W0GQR1XS
NCI-H446NWnkNmJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoTsTWM2OD1{LkC0OVk6KM7:TR?=NE\uV5VUSU6JRWK=
SBC-5NFqwblhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnXWTWM2OD1{LkC2NVQ4KM7:TR?=MUTTRW5ITVJ?
HOSMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIX3[G9KSzVyPUKuNFc3PTNizszNNWjH[Wh{W0GQR1XS
K5NILBUmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnfhTWM2OD1{LkC3PFEyKM7:TR?=M2i2N3NCVkeHUh?=
HLENEHqTWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXzX[GFsUUN3ME2yMlA5PTJ7IN88US=>MofPV2FPT0WU
HSC-2MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHzjS3BKSzVyPUKuNVI5QThizszNMnPCV2FPT0WU
LCLC-97TM1MmnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmiwTWM2OD1{LkG0OVg{KM7:TR?=NWHQTIhwW0GQR1XS
DMS-273NIWxUnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml\6TWM2OD1{LkG0PFM4KM7:TR?=NFfkVVdUSU6JRWK=
TE-8MlXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MULJR|UxRTJwMUW3OlUh|ryPMWXTRW5ITVJ?
DSH1MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1XzemlEPTB;Mj6xOlM6QCEQvF2=NYDXRZM2W0GQR1XS
CAL-51MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2DBd2lEPTB;Mj6xOlY6QSEQvF2=MVvTRW5ITVJ?
IST-SL1MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnzDTWM2OD1{LkG2PFQ1KM7:TR?=NH\FeFZUSU6JRWK=
GCTNF;Ld5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1XlZmlEPTB;Mj6xO|c4KM7:TR?=MlfUV2FPT0WU
SW948M3rHSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXHJR|UxRTJwMUi0OVYh|ryPMmS0V2FPT0WU
NOMO-1MkHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWrRN2JDUUN3ME2yMlE6OzF5IN88US=>MlzMV2FPT0WU
C8166M164b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUTJR|UxRTJwMkGzN|Qh|ryPM4DReXNCVkeHUh?=
OC-314M1zNOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH3UTItKSzVyPUKuNlMzPTlizszNMWLTRW5ITVJ?
CAL-39MoWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVGwT|FSUUN3ME2yMlI{PjJ4IN88US=>MmfHV2FPT0WU
MDA-MB-453NYnNNYVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXzqcGR1UUN3ME2yMlI1Ojd3IN88US=>NVHtUop5W0GQR1XS
A673MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlfuTWM2OD1{LkK1PFYzKM7:TR?=MVzTRW5ITVJ?
HTC-C3NFj5THZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoHzTWM2OD1{LkK2PFUh|ryPMYjTRW5ITVJ?
NCI-H1666MoXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2O1[WlEPTB;Mj6yPFEyOSEQvF2=NUnZ[5NOW0GQR1XS
PSN1NWjX[ncxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlHtTWM2OD1{LkK4PVE{KM7:TR?=Ml\WV2FPT0WU
GI-1MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGrhUIZKSzVyPUKuN|A2PDNizszNMlLiV2FPT0WU
HuH-7NX\Yb|hUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{XG[WlEPTB;Mj6zNFY{PyEQvF2=MmrkV2FPT0WU
JARNEDrOppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWLJR|UxRTJwM{G5PFch|ryPMYnTRW5ITVJ?
5637M1HJTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTJwM{KxNlkh|ryPM37WfnNCVkeHUh?=
GB-1MlLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWjJR|UxRTJwM{KzN|Uh|ryPNHfpfodUSU6JRWK=
KP-N-YSM1zxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWfJR|UxRTJwM{K2NVUh|ryPM2fjdnNCVkeHUh?=
OAW-42MlrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoXCTWM2OD1{LkOzOFE3KM7:TR?=Ml\GV2FPT0WU
8-MG-BAMmD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYDJR|UxRTJwM{O5NFYh|ryPNYSxV3VDW0GQR1XS
RH-18Mn30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M37nXGlEPTB;Mj6zOVAzOiEQvF2=M3flVHNCVkeHUh?=
NCI-H1155M37ETmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH;JeFZKSzVyPUKuN|Y4OjVizszNMke3V2FPT0WU
NB17NUTUdpJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHK4PXlKSzVyPUKuN|gzPDNizszNMnzsV2FPT0WU
NCI-H1437MmjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWTJR|UxRTJwNEG4O|Mh|ryPNVr4O5pZW0GQR1XS
SN12CNFzNUJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2HzXWlEPTB;Mj60N|IyPCEQvF2=NFjwXoFUSU6JRWK=
HSC-3NXXRTIVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEm2XnpKSzVyPUKuOFQ2ODlizszNMlfkV2FPT0WU
GAMGMk[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYDJR|UxRTJwNES1OlEh|ryPM1exfHNCVkeHUh?=
HT-1080MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXXJR|UxRTJwNES4OlQh|ryPNHvVeHBUSU6JRWK=
A549NVfJVoRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWnJR|UxRTJwNES4PVMh|ryPMoDKV2FPT0WU
KNS-62MlnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEi0cIJKSzVyPUKuOFUxPjFizszNNWfxcXhlW0GQR1XS
YKG-1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4XnW2lEPTB;Mj60OVQ{PyEQvF2=M4SyUHNCVkeHUh?=
LU-134-AMmq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXfDW|k6UUN3ME2yMlQ4ODB6IN88US=>MWLTRW5ITVJ?
FADUM1;UfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTJwNEexOlIh|ryPMoHXV2FPT0WU
TGBC11TKBM3\B[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoXBTWM2OD1{LkS3NVc4KM7:TR?=MmnQV2FPT0WU
HT-3M{i2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3POVWlEPTB;Mj60PVU{PSEQvF2=MnjTV2FPT0WU
NCI-H2170M2C5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTJwNUC1OFkh|ryPM{f3c3NCVkeHUh?=
Mo-TM{XUTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlfiTWM2OD1{LkWwPVI4KM7:TR?=NIWzNGdUSU6JRWK=
CCRF-CEMM1fyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVHJR|UxRTJwNUOwOFMh|ryPMXjTRW5ITVJ?
KU-19-19MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGT1Zm9KSzVyPUKuOVM2OTNizszNMl;qV2FPT0WU
NCI-H1048MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1f6S2lEPTB;Mj61OVAzPSEQvF2=NYnFcpRrW0GQR1XS
KOSC-2NF7NNVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn7xTWM2OD1{LkW2NFc3KM7:TR?=NG\ySVBUSU6JRWK=
A431Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlzjTWM2OD1{LkW2N|M2KM7:TR?=MnvGV2FPT0WU
COR-L23NH7XWJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MW\JR|UxRTJwNUi1OlYh|ryPNEPweZJUSU6JRWK=
MKN28NWntdoY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX7qbJhqUUN3ME2yMlU6ODN5IN88US=>NYHDPGdRW0GQR1XS
22RV1NH;XSJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkHzTWM2OD1{LkW5Nlc1KM7:TR?=MWPTRW5ITVJ?
ABC-1MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWTscnlQUUN3ME2yMlYxPDZizszNM2PSU3NCVkeHUh?=
NCI-H2126NVnTeFJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEXrSWhKSzVyPUKuOlA6QDRizszNMlXWV2FPT0WU
DoTc2-4510NW\sOXhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTJwNkKxPFUh|ryPMn\FV2FPT0WU
SCC-4NHvaRppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmrvTWM2OD1{Lk[zNFEzKM7:TR?=NX;zemdVW0GQR1XS
NCI-H661M3u5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVHJR|UxRTJwNkSwPFUh|ryPM{nvUHNCVkeHUh?=
RPMI-2650NIXs[JlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1m2NWlEPTB;Mj62OFE1OyEQvF2=Mly0V2FPT0WU
NCI-H510ANIfqbGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGKx[JFKSzVyPUKuOlQ1OjZizszNNGHtZVJUSU6JRWK=
BPH-1MnfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVjJR|UxRTJwNkW4OUDPxE1?M4XnOnNCVkeHUh?=
M14M2S1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH7OR4lKSzVyPUKuOlY6QTNizszNMVHTRW5ITVJ?
G-402MmDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3LqXmlEPTB;Mj63NFQ2OSEQvF2=MlP1V2FPT0WU
AsPC-1NIf1bXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTJwN{GxO{DPxE1?MWDTRW5ITVJ?
NB12MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX\JR|UxRTJwN{G3NUDPxE1?NFfOUXlUSU6JRWK=
SK-HEP-1NV[zZmdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVnLU2RuUUN3ME2yMlc1OzlzIN88US=>MV3TRW5ITVJ?
U-266M{nk[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTJwN{exNlEh|ryPNXfCblh[W0GQR1XS
AM-38NVrFV3RrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlvmTWM2OD1{Lke3N|U2KM7:TR?=M{TCZnNCVkeHUh?=
PC-14MljmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn6zTWM2OD1{LkiwOVEh|ryPNUDON3h1W0GQR1XS
EGI-1MoHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlzWTWM2OD1{LkixO|Q{KM7:TR?=MXnTRW5ITVJ?
LS-411NMkXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWH0d4lpUUN3ME2yMlgzOzNizszNNF3RZWdUSU6JRWK=
BFTC-905Mn60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXPjboEzUUN3ME2yMlg2PTJ|IN88US=>NFXCclJUSU6JRWK=
CaR-1M1u4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4\5VWlEPTB;Mj64OkDPxE1?M1n4b3NCVkeHUh?=
NCI-H292MmP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnJR|UxRTJwOE[1PVYh|ryPNV3wfm9IW0GQR1XS
8305CMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFzNdm5KSzVyPUKuPFY3PDVizszNMVTTRW5ITVJ?
SNU-449NFvwcXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1[xbGlEPTB;Mj64PVE5OiEQvF2=M1PnZ3NCVkeHUh?=
LCLC-103HMkT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn7WTWM2OD1{LkmwOFM5KM7:TR?=NIXPTotUSU6JRWK=
SW1573M{O0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWXpZ29YUUN3ME2yMlk3ODh{IN88US=>M3\VOHNCVkeHUh?=
MLMAMoXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYCxcVZFUUN3ME2yMlk3PzF5IN88US=>NGjMSFBUSU6JRWK=
NCI-H1355MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn3TTWM2OD1|LkCwO|k3KM7:TR?=MkHKV2FPT0WU
RMG-IMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{j5W2lEPTB;Mz6wNlU6OiEQvF2=MoXnV2FPT0WU
BB65-RCCNVzsXGpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnvOTWM2OD1|LkCzN|E1KM7:TR?=NULvOmY1W0GQR1XS
PC-3Mm\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{f4bmlEPTB;Mz6wN|g4PCEQvF2=MmXTV2FPT0WU
SF268M2TyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTNwMES1NlMh|ryPNFTJTW1USU6JRWK=
NCI-H810MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV;JR|UxRTNwMES4NlMh|ryPNGLGZ5lUSU6JRWK=
MEG-01M1HSdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXTVR2NZUUN3ME2zMlA3OTZ2IN88US=>M2jNT3NCVkeHUh?=
SW13NVexOIpKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWHJR|UxRTNwMEe4OFch|ryPNETXdnNUSU6JRWK=
RH-1NVixW3F2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnG0TWM2OD1|LkGwNlc5KM7:TR?=MVPTRW5ITVJ?
GT3TKBMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYTJR|UxRTNwMUGyPFMh|ryPNXntdGZVW0GQR1XS
TK10MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2KwT2lEPTB;Mz6xN|czPCEQvF2=MorLV2FPT0WU
T-24NIe2Ro9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M173RmlEPTB;Mz6xOVA4KM7:TR?=MX7TRW5ITVJ?
A498MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4r4WGlEPTB;Mz6yNFg4OSEQvF2=M2XQZnNCVkeHUh?=
GR-STMVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGe3UHFKSzVyPUOuNlIyOzlizszNNFX5XWFUSU6JRWK=
LB2518-MELMUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3vPdmlEPTB;Mz6yNlM6QCEQvF2=MYDTRW5ITVJ?
T47DMn[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXPnXJZKUUN3ME2zMlI{PjJ5IN88US=>MWnTRW5ITVJ?
NCI-H1651M3npNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWjTdI1RUUN3ME2zMlI1PjR2IN88US=>M{i3[XNCVkeHUh?=
EC-GI-10NIHwSIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk\mTWM2OD1|LkK2NVU{KM7:TR?=NFfHV2hUSU6JRWK=
HT-29MlfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVHJR|UxRTNwMk[2NVQh|ryPNGn0V45USU6JRWK=
GI-ME-NM{TtWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlfITWM2OD1|LkK5OVEyKM7:TR?=MVvTRW5ITVJ?
SW756M2Hhc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk[0TWM2OD1|LkK5OlI6KM7:TR?=M3\6dXNCVkeHUh?=
RKONVL6clAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGDpR2JKSzVyPUOuN|A4PTdizszNMnTHV2FPT0WU
NCI-H1563NIXROVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGrmR41KSzVyPUOuN|MxOThizszNMWLTRW5ITVJ?
DJM-1Mn2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{C1NWlEPTB;Mz6zO|Y4PCEQvF2=NH\4Z|NUSU6JRWK=
L-428M1Kz[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFzRb3BKSzVyPUOuOFAxPDVizszNMkeyV2FPT0WU
NCI-H2122MnjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1PSemlEPTB;Mz60NVMyOiEQvF2=Mm\pV2FPT0WU
Ca-SkiMYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXfJR|UxRTNwNEW0N{DPxE1?NUnNSlZsW0GQR1XS
639-VNGn3b|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX\JR|UxRTNwNE[wOVch|ryPNVS5Uog4W0GQR1XS
SW1116NWfJV3NTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnW2TWM2OD1|LkS2NlY6KM7:TR?=M2Tj[nNCVkeHUh?=
DMS-114MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn7wTWM2OD1|LkS3NFY3KM7:TR?=NWXsUlc6W0GQR1XS
MZ2-MELNGTiT5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkfKTWM2OD1|LkS3OlgyKM7:TR?=M1XZeXNCVkeHUh?=
COLO-829MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGTuU3RKSzVyPUOuOVAxPzNizszNNXnlN|BtW0GQR1XS
J82MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml3LTWM2OD1|LkWwOVch|ryPNYDFOHF{W0GQR1XS
EW-13M3KzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV3JR|UxRTNwNUK1NUDPxE1?MnHSV2FPT0WU
RXF393MlfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVr5OJg4UUN3ME2zMlU{Ojl2IN88US=>MmC4V2FPT0WU
CAL-62M{jYOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{HRRmlEPTB;Mz61OFUyPCEQvF2=M37ibHNCVkeHUh?=
OCUB-MMWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2fHeGlEPTB;Mz61OFY3PSEQvF2=NYjDSJF5W0GQR1XS
BT-474NV\a[Xp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4nP[mlEPTB;Mz62N|MyKM7:TR?=M2ewb3NCVkeHUh?=
KYSE-180M1XBTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUm2TmJ[UUN3ME2zMlY{Ozd{IN88US=>M3W0RnNCVkeHUh?=
NCI-H650NV7vNZBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHTD[mJKSzVyPUOuOlQzQDdizszNMnLRV2FPT0WU
Detroit562NFHWPIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2nl[mlEPTB;Mz62OVAzOiEQvF2=M2HhOnNCVkeHUh?=
SW48MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnPoTWM2OD1|Lk[1OlU4KM7:TR?=NVLROHhEW0GQR1XS
KYSE-450Mn3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIC2ZW5KSzVyPUOuOlg2QDJizszNM4fNb3NCVkeHUh?=
KYSE-510M1v1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHXLWGZKSzVyPUOuO|IyQDFizszNMWrTRW5ITVJ?
GP5dMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4nFTGlEPTB;Mz63Nlk2KM7:TR?=MWfTRW5ITVJ?
RPMI-7951M1:5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHTOd2hKSzVyPUOuO|Q4OjNizszNNXnaOJNuW0GQR1XS
BeckerMnPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHTwNoVKSzVyPUOuO|UxOTJizszNMVzTRW5ITVJ?
WM-115NHnnbHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYPSWFY{UUN3ME2zMlc5OTl3IN88US=>NGTuNGRUSU6JRWK=
G-401M4LRUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnLjTWM2OD1|Lke5NFg2KM7:TR?=MnHKV2FPT0WU
PANC-08-13MojTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWLJR|UxRTNwN{m2NFIh|ryPNFm4VI9USU6JRWK=
SW982MluxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWjW[4FwUUN3ME2zMlgxPTVzIN88US=>M1rMfnNCVkeHUh?=
D-263MGMl;jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4fWXWlEPTB;Mz64NlA2OSEQvF2=NWTWSm1vW0GQR1XS
KM-H2NFLqUXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3TObmlEPTB;Mz64NlYzPCEQvF2=Mlm0V2FPT0WU
SK-MEL-3NGT5PYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1fI[WlEPTB;Mz64Nlg1OSEQvF2=M2O4O3NCVkeHUh?=
NCI-H1581M4XjRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV;LPGIxUUN3ME2zMlg1PDh6IN88US=>Mm\EV2FPT0WU
LS-123M2Xi[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlLJTWM2OD1|Lki3PVA6KM7:TR?=M2H0cnNCVkeHUh?=
CAKI-1MlfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkPoTWM2OD1|Lki5NFUzKM7:TR?=M2qzNHNCVkeHUh?=
MEL-JUSONWLQTng{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{HUb2lEPTB;Mz64PVE2OyEQvF2=MVTTRW5ITVJ?
HCE-4MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWPSUod7UUN3ME2zMlkyPjZ|IN88US=>M1X3R3NCVkeHUh?=
TE-10Mor3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NITFWllKSzVyPUOuPVIxOSEQvF2=M{jtT3NCVkeHUh?=
OVCAR-4M{jGR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MU\JR|UxRTNwOUK4PFkh|ryPNYSzeXpEW0GQR1XS
ETK-1MmnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGrpNWZKSzVyPUOuPVQ3OzVizszNMlzkV2FPT0WU
A2780NIHTUJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlvvTWM2OD12LkC1PVY3KM7:TR?=M1\qT3NCVkeHUh?=
LU-65MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mof1TWM2OD12LkC3OlM{KM7:TR?=MoTTV2FPT0WU
BHYMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFXNbmVKSzVyPUSuNVI1QTVizszNM37ZXnNCVkeHUh?=
COR-L105NXvpUlJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUnYRXpJUUN3ME20MlE{ODVzIN88US=>NIjBeo9USU6JRWK=
CAL-12TNH7vZpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTRwMUOxNFMh|ryPNFrFeW1USU6JRWK=
SCHNX;rdYdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXPJR|UxRTRwMUW3OFMh|ryPMWHTRW5ITVJ?
CW-2M3vWeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFLkV5hKSzVyPUSuNVkxODFizszNNV3E[WtSW0GQR1XS
HCC1806MnT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWXJR|UxRTRwMkCzNVIh|ryPMUPTRW5ITVJ?
KP-N-YNNUDpS5g4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFX4emtKSzVyPUSuNlA6OjdizszNNVX4S4NLW0GQR1XS
T98GMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHHpb3hKSzVyPUSuNlIyPTdizszNM4HZcHNCVkeHUh?=
CAL-54NGC3PHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUnJR|UxRTRwMkKzPFEh|ryPMV\TRW5ITVJ?
CAL-33MnP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml\tTWM2OD12LkKzNFY1KM7:TR?=M{jOd3NCVkeHUh?=
SNU-C2BNV;tWZFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEfFfpJKSzVyPUSuNlQ4PjlizszNNH7yWI1USU6JRWK=
NUGC-3MonjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVj4cVJuUUN3ME20MlI2PTB3IN88US=>NUnUb5N3W0GQR1XS
DOKNYLpUlh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHfGbW9KSzVyPUSuNlY2QTNizszNMXXTRW5ITVJ?
MMAC-SFNHzjU21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmnuTWM2OD12LkK2PFU6KM7:TR?=NYD0OXpbW0GQR1XS
KYSE-70NWDrW4hQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1rsV2lEPTB;ND6yPVM1KM7:TR?=M17GZnNCVkeHUh?=
A204NVjUcmN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1HuUWlEPTB;ND6zOVgxOyEQvF2=NHSwVYpUSU6JRWK=
SCC-25NFLzTYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX\SWoc1UUN3ME20MlM2QDF7IN88US=>NVfDSnNLW0GQR1XS
EPLC-272HNEXo[FdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTRwM{i5OUDPxE1?NFTjPGFUSU6JRWK=
CAL-120M1vLZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mnr6TWM2OD12LkO4PVkzKM7:TR?=M4nrXXNCVkeHUh?=
LS-513NHHSfVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml:3TWM2OD12LkSyNVk5KM7:TR?=MnLSV2FPT0WU
CAPAN-1MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M17GOmlEPTB;ND60NlM5OiEQvF2=MVPTRW5ITVJ?
ESS-1NVLKcZgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXn2eo5UUUN3ME20MlQzPzJ2IN88US=>M4\BZ3NCVkeHUh?=
GMS-10M1HzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGT5OZZKSzVyPUSuOFI5OTlizszNMYLTRW5ITVJ?
NCI-N87NUfTdFA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1nLfmlEPTB;ND61NFg3QCEQvF2=M321cXNCVkeHUh?=
HMV-IIMlvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4X0OmlEPTB;ND61NVc{KM7:TR?=MlrCV2FPT0WU
COLO-741NH:5eJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWTJR|UxRTRwNUW5PVQh|ryPM1LqZXNCVkeHUh?=
MKN45M3;1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWfJR|UxRTRwNUe3N|Ih|ryPMlj5V2FPT0WU
OAW-28M4TRZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXHJR|UxRTRwNUizPVgh|ryPMX7TRW5ITVJ?
OCI-AML2M4HoS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEfJW2RKSzVyPUSuOlUzOzhizszNNWLyN2NRW0GQR1XS
MDA-MB-231M3rhSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV7JR|UxRTRwN{CyOFMh|ryPMUHTRW5ITVJ?
NCI-H1648M4nTcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkPpTWM2OD12LkeyNlc{KM7:TR?=MmjxV2FPT0WU
NCI-H1792M4XBbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXmwTWZ3UUN3ME20Mlc3OTB5IN88US=>NUSyNI1GW0GQR1XS
GCIYNY\3SHk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MU\JR|UxRTRwN{e0NlQh|ryPM33P[XNCVkeHUh?=
Hs-578-TNHnxbXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnjYTWM2OD12Lke3OlU2KM7:TR?=NHP1e4FUSU6JRWK=
SW962NIfMU2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXHJR|UxRTRwN{iwNVEh|ryPMX\TRW5ITVJ?
NCI-H630MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2rpNWlEPTB;ND63PFA5OSEQvF2=NVHKZXFwW0GQR1XS
786-0NF;qRndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGDGbG5KSzVyPUSuO|g4PzNizszNMoWyV2FPT0WU
FTC-133MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXXJR|UxRTRwN{myOlMh|ryPNELYbnZUSU6JRWK=
BT-20MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYPLVolNUUN3ME20Mlc6PDJ7IN88US=>MmLLV2FPT0WU
MewoM1u4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk\oTWM2OD12LkixO|Q4KM7:TR?=MnfFV2FPT0WU
SW780NV3Ob5BKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnrITWM2OD12Lki1O|Y3KM7:TR?=M4XzV3NCVkeHUh?=
OE33MmW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHrxbWRKSzVyPUSuPFc4OTNizszNMn\EV2FPT0WU
HCC1569M2jLU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2rPWGlEPTB;ND64PFQ2QCEQvF2=Mo[yV2FPT0WU
TE-6MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml3lTWM2OD12LkmzPVc4KM7:TR?=M{Dy[nNCVkeHUh?=
SK-N-FINXjEfVZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFq3[JBKSzVyPUSuPVQ1OjFizszNNVLiUVFNW0GQR1XS
PANC-03-27M3zxbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV7JR|UxRTRwOUm5OlIh|ryPM{LTRnNCVkeHUh?=
MCF7NV;rNWdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYfJR|UxRTVwMEC3N|gh|ryPMYrTRW5ITVJ?
UACC-257NXHLO4ZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn;OTWM2OD13LkCyPFQ2KM7:TR?=MmXaV2FPT0WU
SW1088NI[3cFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MofsTWM2OD13LkCyPVQ1KM7:TR?=MXXTRW5ITVJ?
A704MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NY[0WGVCUUN3ME21MlA{ODZizszNNUP3NpRRW0GQR1XS
A2058NG\aVXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH;tZY1KSzVyPUWuNFU6ODhizszNMWDTRW5ITVJ?
Calu-3MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1fycGlEPTB;NT6wOlQ2OiEQvF2=M3;mZXNCVkeHUh?=
RERF-LC-MSMUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3jDPWlEPTB;NT6wOlkxOyEQvF2=M{PjU3NCVkeHUh?=
AU565NHLJ[VJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFu0fZVKSzVyPUWuNFk4ODJizszNMlL3V2FPT0WU
DMS-79NGHlZoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRTVwMUO4PFMh|ryPM4LZSnNCVkeHUh?=
DK-MGM3HWbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYfwd4s4UUN3ME21MlE5PDN6IN88US=>MojVV2FPT0WU
HuCCT1NF;hbm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV;pTm9VUUN3ME21MlI{QDV4IN88US=>MYnTRW5ITVJ?
HT-144NYr4U2V[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoLiTWM2OD13LkK0PVg4KM7:TR?=MWrTRW5ITVJ?
M059JMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVK3fmZnUUN3ME21MlI2PzZizszNMXXTRW5ITVJ?
COLO-792NIS4N2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1vPTWlEPTB;NT6yOlM2PiEQvF2=NYG4d|FSW0GQR1XS
SF539MmmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NULMWoI2UUN3ME21MlI3PjN{IN88US=>MUHTRW5ITVJ?
SK-UT-1M3u3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFf0b4RKSzVyPUWuNlc4PTFizszNNH;zcWZUSU6JRWK=
NCI-H1703MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{DGS2lEPTB;NT6zOVgzPiEQvF2=MnP4V2FPT0WU
SW837NHjjOFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MULJR|UxRTVwM{e4O|gh|ryPMV3TRW5ITVJ?
U251NUfl[49yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2DK[2lEPTB;NT6zPVA6PiEQvF2=MlWzV2FPT0WU
SW1710MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUHab2dkUUN3ME21MlQyPTV2IN88US=>MWLTRW5ITVJ?
NCI-H1299MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn;sTWM2OD13LkS2N|M2KM7:TR?=NVrZdYpHW0GQR1XS
RVH-421MorBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHXIdmtKSzVyPUWuOFk6ODhizszNNWXSc2VnW0GQR1XS
UM-UC-3NWj3U2k6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NInRbHpKSzVyPUWuOlI3PTFizszNNX75TGtxW0GQR1XS
MDA-MB-175-VIINXnHZZVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGDkepBKSzVyPUWuOlQxPDFizszNMn\WV2FPT0WU
KYSE-270MkTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3XqZWlEPTB;NT62OlA{OSEQvF2=NYDpPYNpW0GQR1XS
COLO-668NYnLWmlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXizcXl1UUN3ME21MlcyOzJizszNMY\TRW5ITVJ?
LN-405NXjGVIZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkPxTWM2OD13LkezNFg2KM7:TR?=MYnTRW5ITVJ?
HT-1376M2CyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHHUc29KSzVyPUWuO|gxPTJizszNMmfSV2FPT0WU
769-PNYW4OIpuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4\MXGlEPTB;NT64OlcyQCEQvF2=NGPRNJJUSU6JRWK=
HuP-T3M2jCemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVfUc|E6UUN3ME21Mlg5Pjd5IN88US=>NXzpPGViW0GQR1XS
MDA-MB-415M3fMPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXvJR|UxRTVwOUKxN|kh|ryPNYS3[Ip1W0GQR1XS
MKN7MmLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4PYd2lEPTB;NT65PFgh|ryPNYnjOYx3W0GQR1XS
KS-1MlHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH:zUJNKSzVyPUWuPVg5OzZizszNNXu1SZBlW0GQR1XS
647-VMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4DvfWlEPTB;NT65PVE1QCEQvF2=NUnScnBiW0GQR1XS
COLO-679M3L2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoTGTWM2OD14LkCwNlU2KM7:TR?=MX7TRW5ITVJ?
AN3-CAMXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGXXN5VKSzVyPU[uNFM1PDFizszNM4fRWHNCVkeHUh?=
C32M{T2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkHsTWM2OD14LkGzNFM1KM7:TR?=NUDnRW9EW0GQR1XS
KM12NV\LV28yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHTvb4NKSzVyPU[uNlQxQTlizszNNIXu[m9USU6JRWK=
KINGS-1NEnNTpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NELHVpRKSzVyPU[uNlYyPTJizszNM13hbXNCVkeHUh?=
KYSE-410NYm2fGl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4OybGlEPTB;Nj6zNFY1PSEQvF2=Ml60V2FPT0WU
HPAF-IIMmWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1zZR2lEPTB;Nj6zOVQ5KM7:TR?=MW\TRW5ITVJ?
LAN-6M3z6V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml2wTWM2OD14LkS5OlMyKM7:TR?=M4nubXNCVkeHUh?=
LU-99AMlTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHXz[m5KSzVyPU[uOVU6QDlizszNNUKzeGhyW0GQR1XS
SJSA-1MnfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmPUTWM2OD14LkW2N|Q4KM7:TR?=NX7iWHFQW0GQR1XS
MSTO-211HNGO4VGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWPWNmQ{UUN3ME22MlczOjN|IN88US=>NU\VeFBYW0GQR1XS
SW900MlHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGPhcYZKSzVyPU[uO|YzOjFizszNM134ZnNCVkeHUh?=
LNCaP-Clone-FGCMnzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGeye5RKSzVyPU[uPFA1ODNizszNMUTTRW5ITVJ?
OMC-1NUL2[JE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYrJR|UxRTZwOEW0NFIh|ryPNFS0[GhUSU6JRWK=
IST-MEL1NYOxXFBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUXGV2ZsUUN3ME22Mlg6PjZ7IN88US=>M4LvfHNCVkeHUh?=
TE-9MmfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoLGTWM2OD14Lki5PFQ4KM7:TR?=NX7TeG5QW0GQR1XS
NCI-H2030NYXwcIxOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mlj0TWM2OD14LkmxNlI3KM7:TR?=MX7TRW5ITVJ?
BFTC-909MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{PidGlEPTB;Nz6wNFY1OSEQvF2=NY\KemZPW0GQR1XS
NCI-SNU-5M3XwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTdwMEKxOVkh|ryPMmPYV2FPT0WU
TE-5M1TpS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIrKWI5KSzVyPUeuNFI5QDFizszNNHHzVItUSU6JRWK=
SK-MES-1MnOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFzWfldKSzVyPUeuNFU1OjdizszNNUn3SHg2W0GQR1XS
SHP-77M{LvSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEL4bXdKSzVyPUeuNVM6PTJizszNMl;YV2FPT0WU
NCI-H1623M{CyeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEXQdZlKSzVyPUeuNVQxPzJizszNNHvnTGtUSU6JRWK=
TE-11NWX4dZhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NELifFJKSzVyPUeuNVUyQDRizszNNGjubZpUSU6JRWK=
EKVXNEf6b5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWPtZ21VUUN3ME23MlE6OjZ5IN88US=>MUHTRW5ITVJ?
OVCAR-3M3XrXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUDxbZdoUUN3ME23MlIyOTN|IN88US=>NUTtdFBuW0GQR1XS
C3AMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX3SfoFxUUN3ME23MlM1PTJizszNMX7TRW5ITVJ?
CFPAC-1NU\XOnFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3rsOmlEPTB;Nz6zOlIzOiEQvF2=MnnmV2FPT0WU
MG-63M4noWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGnYXWdKSzVyPUeuOFE5PDlizszNNETTOVBUSU6JRWK=
KYSE-140MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF\yRZlKSzVyPUeuOFQxPjFizszNMoq3V2FPT0WU
MPP-89NYnGSJA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3TlWGlEPTB;Nz61PVczQSEQvF2=M4HFWXNCVkeHUh?=
COLO-824MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4fnd2lEPTB;Nz63Nlg3OyEQvF2=MmX1V2FPT0WU
SiHaMlXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHriRVZKSzVyPUeuPFM4ODdizszNMWrTRW5ITVJ?
SNU-387M3e2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1fuTGlEPTB;Nz64OVM1PyEQvF2=MkPtV2FPT0WU
A172NHqwfINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NILTU2pKSzVyPUeuPFYyPzJizszNMnjCV2FPT0WU
COLO-680NMWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnfwTWM2OD15LkmxO|Mh|ryPMWTTRW5ITVJ?
HCC1395Mlj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoDwTWM2OD16LkC1OFUzKM7:TR?=NYDmW2h5W0GQR1XS
NCI-H28MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkG3TWM2OD16LkC1PVY{KM7:TR?=Mnm5V2FPT0WU
LC-2-adMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXjKNo1uUUN3ME24MlIyQTN5IN88US=>MYDTRW5ITVJ?
S-117NWLX[pRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW\JR|UxRThwMkWzOVMh|ryPMUTTRW5ITVJ?
NCI-H1838Mk[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIfvUmdKSzVyPUiuNlU4QDFizszNM4j5NXNCVkeHUh?=
PANC-10-05M1vjemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIX5fo5KSzVyPUiuN|cxPDdizszNNXn2Rno5W0GQR1XS
KALS-1MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mo\sTWM2OD16LkWwPVI5KM7:TR?=NYXlNWgzW0GQR1XS
LS-1034MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUHJR|UxRThwNUe0N|ch|ryPMkDkV2FPT0WU
TGBC1TKBM3;qdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXfJR|UxRThwN{O1N|Uh|ryPNFO5[opUSU6JRWK=
OE19M4ntWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUOwSZdkUUN3ME24Mlc3OjZ{IN88US=>NETFSHBUSU6JRWK=
D-502MGMlXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnHLTWM2OD16Lke2PVk1KM7:TR?=MUPTRW5ITVJ?
JEG-3NELNdWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mmm0TWM2OD16Lke4OlE5KM7:TR?=NHXmUINUSU6JRWK=
DBTRG-05MGNUHhSopoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlP4TWM2OD16Lki3OVY2KM7:TR?=M2PVfXNCVkeHUh?=
ME-180MkG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXPJR|UxRTlwME[3NlUh|ryPMlX6V2FPT0WU
NCI-H1573MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEn0b4VKSzVyPUmuNVA2OzJizszNM3zzSnNCVkeHUh?=
HCC2998MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWrPVWtjUUN3ME25MlE{PjhzIN88US=>Mli1V2FPT0WU
ACHNMmrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWL6U|Q{UUN3ME25MlI1QTd3IN88US=>M2L2dnNCVkeHUh?=
D-392MGNHrBb4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXjjOJNQUUN3ME25MlI2PzF3IN88US=>NX;nUHdlW0GQR1XS
no-11MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1fndGlEPTB;OT6yOlAzQCEQvF2=NFjtcm1USU6JRWK=
KLENGnCbVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYHJR|UxRTlwM{KyN|Ih|ryPM4LHWHNCVkeHUh?=
Calu-6MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{PHTGlEPTB;OT6zO|UzQCEQvF2=NYruS5FQW0GQR1XS
LB831-BLCNXO0R3htT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEPM[|NKSzVyPUmuOFUyPzFizszNNFrYSmVUSU6JRWK=
SW684M{Xy[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlrZTWM2OD17LkS2NVE3KM7:TR?=M2X4VHNCVkeHUh?=
SH-4M3PZZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYTJR|UxRTlwNEmzOlQh|ryPMoPtV2FPT0WU
IST-MES1NHfHOWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWK3ZmJ{UUN3ME25MlUyPjR2IN88US=>MlPLV2FPT0WU
Saos-2MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWXhbYRHUUN3ME25MlUzOTl3IN88US=>NWi4fo5mW0GQR1XS
NCI-H2087MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUDrOIJuUUN3ME25MlY4OzV{IN88US=>MVrTRW5ITVJ?
SCC-9M3O5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4DJNWlEPTB;OT63NVgyPiEQvF2=NGj6SVVUSU6JRWK=
MFE-280MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF;ifpBKSzVyPUmuO|I4QDVizszNM4TpTXNCVkeHUh?=
BENM2e0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlT5TWM2OD17LkiyNVU6KM7:TR?=NEHSemlUSU6JRWK=
CP50-MEL-BNEm3eJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHnud45KSzVyPUmuPVI1OzJizszNNVnGdYdsW0GQR1XS
SK-MEL-28MmPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIm1U|NKSzVyPUGwMlAyQTNizszNNU\ORpR3W0GQR1XS
NCI-H2452NHSybJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRTFyLkG2JO69VQ>?MoPWV2FPT0WU
NCI-H1395MnzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Moi0TWM2OD1zMD6xO|gh|ryPMl3GV2FPT0WU
NCI-H2052M1\SXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYPXVolOUUN3ME2xNE4yQDh{IN88US=>MYnTRW5ITVJ?
A375NXzaVo1ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX6yU4gxUUN3ME2xNE4zPDV{IN88US=>MmHQV2FPT0WU
HCC38MnHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV7yVFJFUUN3ME2xNE4{OjJizszNM13ITXNCVkeHUh?=
LK-2NHLpXodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{XvSGlEPTB;MUCuOFIxQCEQvF2=M1foZ3NCVkeHUh?=
SF126MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXLJR|UxRTFyLkS3Nlch|ryPNFnSOpdUSU6JRWK=
SK-MEL-1NFLOOI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEfke3FKSzVyPUGwMlc5OzhizszNNX7iSZdKW0GQR1XS
ACNNV;3W3B4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1vDSWlEPTB;MUCuPFY4QSEQvF2=MnPUV2FPT0WU
BB30-HNCNHzCe4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MULJR|UxRTFyLki3NVEh|ryPMWHTRW5ITVJ?
NCI-H747M1P1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnfvTWM2OD1zMD64O|Q3KM7:TR?=MVrTRW5ITVJ?
KYSE-150NUDsOXo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF7kTIFKSzVyPUGxMlA{QDdizszNMYDTRW5ITVJ?
D-247MGMlP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NULhRWg{UUN3ME2xNU4yODB7IN88US=>MnS1V2FPT0WU
BxPC-3M1;COGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NETsZnBKSzVyPUGxMlM4PDdizszNNWrlTnFtW0GQR1XS
SK-MEL-30M3X4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYjJR|UxRTFzLkSwO|kh|ryPMUfTRW5ITVJ?
CAS-1MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnfiTWM2OD1zMT60NVA6KM7:TR?=NUiwXmZkW0GQR1XS
no-10MlSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYnJR|UxRTF{LkGyNVch|ryPNXvmRWJMW0GQR1XS
NCI-H2405M3jFfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTF{LkKwN|Yh|ryPM3XoZnNCVkeHUh?=
KGNM{fyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2L5OWlEPTB;MUKuNlkxOSEQvF2=MUDTRW5ITVJ?
BB49-HNCM3e0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHuxdoRKSzVyPUGyMlM6PTZizszNMX3TRW5ITVJ?
NCI-H1693M2PYWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUnGSYxlUUN3ME2xNk42QDF4IN88US=>M1HXXHNCVkeHUh?=
RO82-W-1M3\lemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIHBO2RKSzVyPUGzMlA3PDlizszNNULOWod{W0GQR1XS
CAL-85-1NYTUVVYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NInWXJBKSzVyPUGzMlQ{QTlizszNNGrIZ2lUSU6JRWK=
H-EMC-SSMnPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4riZ2lEPTB;MUOuPVExPCEQvF2=M1TiTnNCVkeHUh?=
SW1783M{OwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoTtTWM2OD1zND6yN|kyKM7:TR?=MWrTRW5ITVJ?
LB771-HNCM4jj[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFu0U5RKSzVyPUG0MlQyQSEQvF2=NHLLPItUSU6JRWK=
HCC70Mm\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXnJR|UxRTF2LkSyN|Mh|ryPNIj0fnBUSU6JRWK=
KNS-81-FDNIfpNXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTF2LkewOFUh|ryPMVPTRW5ITVJ?
KYSE-520M{LCVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1vXfWlEPTB;MUSuPVI4KM7:TR?=NYLyVZY5W0GQR1XS
TGBC24TKBMl\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoDDTWM2OD1zND65OVM6KM7:TR?=MYfTRW5ITVJ?
SNB75MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MorYTWM2OD1zNT6wO|I6KM7:TR?=NU\HN4tsW0GQR1XS
SW872MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFfVXJhKSzVyPUG1MlIzOThizszNNYXp[YRVW0GQR1XS
U031Ml7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIrkW5hKSzVyPUG1MlgxOjhizszNNXz4Vm82W0GQR1XS
ChaGo-K-1M13xOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYTJR|UxRTF3LkizOVkh|ryPMlPPV2FPT0WU
NCI-H441M17SZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MU\JR|UxRTF4LkCwN|kh|ryPM2X6SXNCVkeHUh?=
TE-12MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWnvTlgxUUN3ME2xOk4yQDd|IN88US=>NHTneZFUSU6JRWK=
NCI-H1755M1PEPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEPmSINKSzVyPUG2MlU4OyEQvF2=MmL2V2FPT0WU
KNS-42M2fXPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{LKfGlEPTB;MU[uOlU5QSEQvF2=MUHTRW5ITVJ?
SK-PN-DWM2XGcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3Sx[WlEPTB;MUeuOFIxOSEQvF2=M4T4dXNCVkeHUh?=
NCI-H226MmLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml\tTWM2OD1zNz65N|Q2KM7:TR?=NGDXSmNUSU6JRWK=
K-562M1r0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVTJeJQ3UUN3ME2xPE43OzF5IN88US=>NVPGZY81W0GQR1XS
A388NGjvTIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUHJR|UxRTF7LkCzNFMh|ryPM2e2[3NCVkeHUh?=
ZR-75-30MnjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXfJR|UxRTF7LkC5Olgh|ryPMYLTRW5ITVJ?
LU-135MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmfTTWM2OD1zOT6yOlM3KM7:TR?=MlLyV2FPT0WU
NCI-H2029MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MULJR|UxRTF7Lk[wNlEh|ryPM{XjWXNCVkeHUh?=
HT-1197NUTGR2lKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnS3TWM2OD1zOT65NlI4KM7:TR?=NGPWeYZUSU6JRWK=
IGR-1MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NETobHdKSzVyPUKwMlMyOTdizszNNXvCfmpOW0GQR1XS
U-87-MGMUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4rjN2lEPTB;MkCuOlQyOyEQvF2=M4jsZ3NCVkeHUh?=
NCI-H1304NVnwdJlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnvRTWM2OD1{MD63OVAyKM7:TR?=NGnlW3FUSU6JRWK=
RCC10RGBMl\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGXTO|JKSzVyPUKxMlI5OjlizszNM1zL[HNCVkeHUh?=
NCI-H520MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmHDTWM2OD1{Mj63OlEyKM7:TR?=NV;4TIE2W0GQR1XS
SK-LU-1MnLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXLJR|UxRTJ|LkC3NVgh|ryPMmfvV2FPT0WU
UACC-893M2XEZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnPoTWM2OD1{Mz6xNFM5KM7:TR?=MlPsV2FPT0WU
NCI-H2347NG\4b4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mki0TWM2OD1{Mz6yOlc1KM7:TR?=NXvXWFkxW0GQR1XS
U-118-MGM1vkemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRTJ|LkeyNVch|ryPMV3TRW5ITVJ?
NCI-H596NHjzNnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NITFRlFKSzVyPUKzMlkxPTVizszNNVzTeZhoW0GQR1XS
MZ1-PCNHTkZ3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3fhZ2lEPTB;MkSuOlc2QSEQvF2=M4XaO3NCVkeHUh?=
SW1417MkjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mni4TWM2OD1{NT6yOFk5KM7:TR?=MkjsV2FPT0WU
NCI-H82MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mor5TWM2OD1{Nj60Nlg5KM7:TR?=NUK4Z4EyW0GQR1XS
COLO-678MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmjkTWM2OD1{Nz60PVE6KM7:TR?=NEKxfWpUSU6JRWK=
KURAMOCHIM3HwPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYTJR|UxRTJ6LkGyOkDPxE1?MVfTRW5ITVJ?
NCI-H1650MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUDz[IFiUUN3ME2zNE4yQTJ2IN88US=>MlTaV2FPT0WU
HCC1954M1jSfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHPVfYlKSzVyPUOxMlM3PjZizszNNYPlN5lZW0GQR1XS
GAKNIHxTGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2raeWlEPTB;M{KuNlYyPiEQvF2=MUjTRW5ITVJ?
YAPCMVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{fqSGlEPTB;M{OuO|Y1QCEQvF2=MnLrV2FPT0WU
NCI-H2228NFf3XGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYX0W|czUUN3ME2zOE4{PjB3IN88US=>MnrOV2FPT0WU
VMRC-RCZNX3YOlJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFXjd5FKSzVyPUO2MlMxOjJizszNNGnNflBUSU6JRWK=
NMC-G1NXyzTnJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXLJR|UxRTN5LkC1Nlkh|ryPMV;TRW5ITVJ?
D-336MGNX;HZnFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX3JR|UxRTRzLki0OFIh|ryPM{fYd3NCVkeHUh?=
UACC-62Mm\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NU\3WGJJUUN3ME20Nk42PTB3IN88US=>MlrBV2FPT0WU
C-33-AM{Did2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFq0bYtKSzVyPUS1MlMzPTZizszNNHPiR3JUSU6JRWK=
HCC1937NGC3S2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX\X[5ZzUUN3ME20O{4yQTV6IN88US=>NXLqUVRsW0GQR1XS
HDLM-2NFm3[HJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NE\XWlFKSzVyPUS3MlIzQDdizszNNWnZW4RwW0GQR1XS
NCI-H727NWTBT4RRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MonoTWM2OD12Nz6yOFUyKM7:TR?=M{nQc3NCVkeHUh?=
NYMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlTJTWM2OD12OT6zPVA5KM7:TR?=NX73bFBwW0GQR1XS
NCI-H2291NHOxcFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn:0TWM2OD12OT64N|AyKM7:TR?=NH;0S4ZUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Administration of Vorinostat (~100 mg/kg/day) significantly inhibits the growth of CWR22 human prostate xenografts in nude mice with tumor reductions of 78%, 97% and 97%, at doses of 25 mg/kg/day, 50 mg/kg/day and 100 mg/kg/day, respectively, compared with control. Vorinostat induces the accumulation of acetylated core histones and prostate-specific antigen mRNA expression in CWR22 cells, resulting in higher levels of serum prostate-specific antigen than predicted from tumor volume alone. [2] Oral administration of Vorinostat (0.67g/L) crosses the blood-brain barrier, increases histone acetylation in the brain, and dramatically improves the motor impairment in the R6/2 mice model of Huntington's disease. [5]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

Immunoprecipitation-HDAC assays The lysate of Jurkat cells is incubated for 1 hour on ice and cleared by centrifugation at 12,000 g for 10 minutes at 4 °C. Supernatants are precleared with 30 μL of 50% protein G-Sepharose slurry for 1 hour at 4 °C. Beads are pelleted by centrifugation and supernatants are incubated for 1 hour at 4 °C with 10 μg of IgG fraction from anti-HDAC1 or HDAC3 polyclonal antisera (preincubated 2 hours at room temperature with either the homologous or heterologous immunizing peptide). Both antisera are raised in rabbits against the carboxylterminal peptide of HDAC1 and HDAC3 by using synthetic peptides coupled to keyhole limpet hemocyanin. 30 μL of 50% protein G-Sepharose slurry is added for 1 hour at 4 °C. Immune complexes are pelleted by centrifugation and washed three times with 1 mL of lysis buffer. Beads are resuspended in 200 μL of HDAC buffer (20 mM Tris-HCl, pH 8.0/150 mM NaCl/10% glycerol), and the HDAC assay is performed with an 3H-acetylated peptide corresponding to amino acids 1-24 of histone H4. Released [3H]acetic acid is quantified by scintillation counting. For inhibitions studies, the immunoprecipitated complexes are preincubated with the different concentrations of Vorinostat for 30 minutes at 4 °C.

Cell Assay:

[2]

Cell lines LNCaP, PC-3, and TSU-Pr1
Concentrations Dissolved in DMSO, final concentrations ~7.5 μM
Incubation Time 1, 2, 3 and 4 days
Method

Cells are exposed to various concentrations of Vorinostat for 1, 2, 3 and 4 days. Cell viability is assessed by trypan blue dye exclusion.

Animal Study:

[2]

Animal Models Male BALB/c nude (nu/nu) mice implanted with CWR22 tumor cells
Formulation Dissolved in DMSO
Dosages ~100 mg/kg/day
Administration Injection i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Richon VM, et al. Proc Natl Acad Sci U S A, 1998, 95(6), 3003-3007.

[2] Butler LM, et al. Cancer Res, 2000, 60(18), 5165-5170.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-05-29)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02589145 Not yet recruiting Lymphoma M.D. Anderson Cancer Center|Celgene Corporation August 2016 Phase 1|Phase 2
NCT02707900 Not yet recruiting HIV-1 Infection Cynthia L Gay, MD|National Institute of Allergy and Infec  ...more Cynthia L Gay, MD|National Institute of Allergy and Infectious Diseases (NIAID)|University of North Carolina, Chapel Hill March 2016 Phase 1
NCT02638090 Recruiting Lung Cancer|Non-small Cell Lung Cancer H. Lee Moffitt Cancer Center and Research Institute|Merck  ...more H. Lee Moffitt Cancer Center and Research Institute|Merck Sharp & Dohme Corp. February 2016 Phase 1|Phase 2
NCT02619253 Recruiting Renal Cell Carcinoma|Urinary Bladder Neoplasms Roberto Pili|Indiana University January 2016 Phase 1|Phase 2
NCT02336074 Recruiting HIV Imperial College London|Medical Research Council|Universi  ...more Imperial College London|Medical Research Council|University of Oxford|University of Cambridge|Chelsea and Westminster NHS Foundation Trust|Royal Free Hospital NHS Foundation Trust|Brighton and Sussex University Hospitals NHS Trust|Guys and St Thomas NHS Foundation Trust|Central and North West London NHS Foundation Trust November 2015 Phase 2

view more

Chemical Information

Download Vorinostat (SAHA, MK0683) SDF
Molecular Weight (MW) 264.3
Formula

C14H20N2O3

CAS No. 149647-78-9
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 53 mg/mL (200.52 mM)
Ethanol 3 mg/mL (11.35 mM)
Water <1 mg/mL (<1 mM)
In vivo 2% DMSO+30% PEG 300+ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name N1-​hydroxy-​N8-​phenyl-octanediamide

Customer Product Validation (20)


Click to enlarge
Rating
Source Nat Biotechnol 2011 29, 255-265. Vorinostat (SAHA, MK0683) purchased from Selleck
Method Immunofluorescence analysis
Cell Lines K562 cells
Concentrations 5 µM
Incubation Time 6 h
Results SAHA and other nonselective HDAC inhibitors increased steady-state acetylation of tubulin and histones manifested by the staining of acetylated microtubules and punctuate nuclear staining of acetylated histone.

Click to enlarge
Rating
Source Nature 2011 471, 235-9. Vorinostat (SAHA, MK0683) purchased from Selleck
Method MTT cell viability assay
Cell Lines T-ALL cell lines
Concentrations 0.01-100 uM
Incubation Time 72 h
Results It examined responsiveness to dexamethasone and the class I/II HDAC inhibitor vorinostat in a panel of T-ALL cell lines with wild type or mutant CREBBP alleles. This demonstrated sensitivity to vorinostat at clinically useful concentrations (IC50 below 1礛) in the majority of cell lines tested.

Click to enlarge
Rating
Source J Exp Med 2012 209, 35-50. Vorinostat (SAHA, MK0683) purchased from Selleck
Method Western blot
Cell Lines BM cells
Concentrations 100 ug/g
Incubation Time 11 days
Results Because of the observed decrease in global histone H3 acetylation, It treated NF-E2 tg mice with the HDAC-I vorinostat (SAHA) to restore physiological levels of histone H3 acetylation. Vorinostat treatment significantly increased H3 acetylation in NF-E2 tg animals.

Click to enlarge
Rating
Source Clin Cancer Res 2012 18, 3822-33. Vorinostat (SAHA, MK0683) purchased from Selleck
Method Western blotting
Cell Lines LNCaP/22Rv1 cells
Concentrations 0.5/1μM
Incubation Time 24 h
Results The apoptosis induced by 0.5μM or 1μM SAHA was significantly increased in cells co-treated with 10μM bicalutamide; this was paralleled by demonstrable knockdown of c-FLIPL and c-FLIPS expression in these cells and by an enhanced level of cleaved PARP protein (Figure A/B). At the highest concentration of SAHA, co-treatment induced a rise of caspase-8 and caspase-3/7 activity to 245.3±28.9% and 265.5±15.6%, respectively (Figure C, left panel). Similarly, in LNCaP cells, caspase activity was augmented in response to SAHA and SAHA/bicalutamide; where there was a > 3-fold increase in caspase 3/7 activity with 2μM SAHA in combination with bicalutamide (Figure C, right panel). To confirm the importance of caspase-8 in initiating drug-induced apoptosis, caspase-8 activity was inhibited by the addition of Z-IETD-fmk prior to the drug treatments (Figure D).

Click to enlarge
Rating
Source Diabetologia 2012 55, 2421-2431. Vorinostat (SAHA, MK0683) purchased from Selleck
Method Analyses of efficacy, potency and IC50
Cell Lines INS-1 cells
Concentrations
Incubation Time
Results HC toxin, CI-994, PCI24781 and LAQ824 all protected against cytokine-induced beta cell death, whereas the HDAC8-selective inhibitor PCI34051 showed no protection.

Click to enlarge
Rating
Source Mol Carcinog 2012 52, 459-74. Vorinostat (SAHA, MK0683) purchased from Selleck
Method Real-Time Cell Growth Analysis
Cell Lines HT29/HCT116 cells
Concentrations 1-3 μM
Incubation Time 48 h
Results Treatment of HT29 and HCT116 CRC cells with increasing concentrations of butyrate or SAHA led to decreased proliferation over a 48 h period.

Click to enlarge
Rating
Source J Neurochem 2012 123 Suppl 2, 108-15. Vorinostat (SAHA, MK0683) purchased from Selleck
Method Confocal microscopy/pixel-intensity measurements
Cell Lines mouse optic nerves
Concentrations 5 μM
Incubation Time
Results Suberoylanilide hydroxyamic acid (SAHA) preserves CFP (+) expression in mouse optic nerves (MONs) from older mice.

Click to enlarge
Rating
Source J Transl Med 2011 9, 37. Vorinostat (SAHA, MK0683) purchased from Selleck
Method Tumor xenograft studies
Cell Lines female athymic nude mice
Concentrations 25 mg/kg
Incubation Time two weeks
Results SAHA , it self showed some anti-cancer effect in two tumor models ( Figure D and E). However, when mice were treated with S AHA followed by IL-13-PE, a significant decrease in tumor size was observed. In addition, 50% of mice showed complete elimination of their tumors in combination group. Next, we e valuated anti-cancer effect of combination of SAHA and IL-13-PE in IL-13Ra 2-positive pancreatic cancer model (HS766T and M IA -PaCa2). We observed that IL-13 - PE could significantly decrease tumor size in both IL-13Ra 2- positive tumors (Figure F and G). But when combined with SAHA , IL-13-PE not only decreased tumor size but also completely eliminated tumors in 66 to 83% of mice. These data suggest that SAHA can enhance anti-cancer effect of IL-13-PE even in IL-13Ra 2-positive pancreatic cancers.

Click to enlarge
Rating
Source J Transl Med 2011 9, 37. Vorinostat (SAHA, MK0683) purchased from Selleck
Method qRT-PCR/immunostaining
Cell Lines female athymic nude mice
Concentrations 25 mg/kg
Incubation Time two weeks
Results Human IL-13Rα2 mRNA was significantly increased in tumors in both SAHA treated mice (Figure A). IL-13-PE treatment had no effect by itself but in combination with SAHA , a significant decrease in IL-13Rα2 expression was observed. In contrast, none of the organs except brain showed a modest increase in mouse IL-13Rα2 mRNA expression (Figure B). We also examined IL-13Rα2 protein expression by IHC. Similar to mRNA results, human IL-13Rα2 was dramatically increased in tumors from SAHA treated mice and when combined with IL-13 - PE, a decrease in IL-13Rα2 expression was observed ( Figure C ) . In normal tissues, mouse IL-13Rα2 was not detected or levels were below the detection limit of the assay in all organs examined (Figure D).

Click to enlarge
Rating
Source Exp Dermatol 2010 19, 1096-1102. Vorinostat (SAHA, MK0683) purchased from Selleck
Method Tumor volume measurement
Cell Lines MyLa2059 cells
Concentrations 60 mg/kg
Incubation Time
Results The tumor growth was suppressed in mice treated with vorinostat when compared to mice treated with vehicle.

Click to enlarge
Rating
Source Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck
Method Western blot
Cell Lines BT-474 cells
Concentrations 0-10 μM
Incubation Time 8 h
Results Proteolytic processing of the caspase substrate PARP, a hall mark of apoptosis, increased in the BT-474 cells treated with SAHA and TRAIL.These results demonstrate that the combined treatment with SAHA and TRAIL induces significant apoptosis in these breast cancer cell lines.The activation of caspase-8 induced by TRAIL was clearly enhanced by pre-treatment with SAHA.The amount of intact Bid clearly diminished in the cells treated with both SAHA and TRAIL when compared to the cells treated with TRAIL or SAHA alone(Fig.a).The cellular levels of both cFLIPL and cFLIPS protein decreased in a dose-depen dent manner following exposure to SAHA, where as the levels of other prote ins in the TRAIL signalling pathway were not affected by SAHA (Fig.b)

Click to enlarge
Rating
Source Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck
Method Analysis of apoptosis
Cell Lines BT-474 cells, MDA-MB-231 cells
Concentrations 0-10 µM
Incubation Time 8 h
Results When the cells were exposed to SAHA for 8 h prior to the overni ght addition of TRAIL , apoptotic cell death was increased signifi cantly in both cell lines, particularly in the highly resistant BT-474 cells that over-expre s the ErbB2 /Her-2/ neu oncogene.

Click to enlarge
Rating
Source Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck
Method Western blot
Cell Lines BT-474 cells
Concentrations 5 µM
Incubation Time 8 h
Results Both MG132 and epoxomycin blocked the down-regulation of the two cFLIP isoforms induced by SAHA in BT-474 cells (Fig. a).even though siRNA treatment effectively depleted Itch/AIP4 in SAHA-treated cells, its depletion did not influence the down-regulation of cFLIP proteins (Fig. b).

Click to enlarge
Rating
Source Invest New Drugs 2012 30, 541-547. Vorinostat (SAHA, MK0683) purchased from Selleck
Method Analysis of apoptosis, Western blot
Cell Lines BT-474 cells
Concentrations 0-10 μM
Incubation Time 8 h
Results Cells over-expressing cFLIPL were clearly more resistant to SAHA-induced sensitization to TRAIL-mediated apoptosis than cells expressing normal cFLIP levels (Fig. b)

Click to enlarge
Rating
Source BMC Neurosci 2011 12, 50. Vorinostat (SAHA, MK0683) purchased from Selleck
Method Flow cytometry/Western blot
Cell Lines NSCs
Concentrations 1 μM
Incubation Time 48 h
Results Western blot analysis of whole cell extracts from adult NSCs treated with HDACi for 48 hours confirms SAHA and NaB treatment results in an increase inhistone3 (H3)acetylation levels when compared to DMSO and water vehicle controls (Figure a). Qu antita-tive an alysis of adult NSCs after 7-days HDACi treatment confirms SAHA and NaB treatment dramatically inhibits the formation of neurospheres (diameter≥ 50 μm) and increase the prevalence of small (≥ 4 cells,diameter < 50 μm) cell clusters in culture (Figure c ). flow cytometry reveals SAHA and NaB exposureresults in a 10 % reduction in cell viability compared to vehicle controls after 48 hours treatment (Figure d).

Click to enlarge
Rating
Source BMC Neurosci 2011 12, 50. Vorinostat (SAHA, MK0683) purchased from Selleck
Method Flow cytometry/Fluorescence micrographs
Cell Lines NSCs
Concentrations 1 μM
Incubation Time 16 h
Results The addition of either SAHA or NaB significantly inhibited DNA synthesis in adult mouse NSCsin vitro. these flow cytometry data indicate that the suppression of NSC proliferation by SAHA and NaB result s in a G1-to-S phase block in cell cycle progression.

Click to enlarge
Rating
Source BMC Neurosci 2011 12, 50. Vorinostat (SAHA, MK0683) purchased from Selleck
Method immunofluorescence cell fate assay/Western blot
Cell Lines NSCs
Concentrations 1 μM
Incubation Time 48 h
Results SAHA significantly reduced glial (p < 0.001) and oligodendrocyte (p < 0.05) differentiated cell fate in culture w hen compared to DMSO vehicle controls (Figure a). Fold-changes of b-catenin nuclear protein levels normalized to laminin A/C reveal marginal opposing +/- effects of SAHA (-1.49 ± 0 .11) and NaB (1.36 ± 0.33) treatment, indicating SAHA modulates cell fate via mechanisms independent of increased β-catenin stabilization.

Click to enlarge
Rating
Source Pediatr Surg Int 2012 28, 579-89. Vorinostat (SAHA, MK0683) purchased from Selleck
Method DAPI staining and microscopy/ Western blot
Cell Lines HUH6 cells/ HepT1 cells
Concentrations 0.2/0.5 μM
Incubation Time 72 h
Results The effect of VX-680 and/or SAHA on cell morphology was similar in both, HepT1 and HUH6 cells (Fig. b). There was also a significant increase in both the nuclei and cell diameter in HepT1 cells when treated with VX–680 alone or in combination. In both HB cell. As shown in Fig. c, In both HB cell lines treatment with VX–680 and the combination with SAHA led to a decrease in histone H3 phosphorylation.

Click to enlarge
Rating
Source Dr. Akihiko Yoshimura of Akihiko Yoshimura. Vorinostat (SAHA, MK0683) purchased from Selleck
Method Hoechst staining
Cell Lines C2C12 cells
Concentrations
Incubation Time
Results

Click to enlarge
Rating
Source Dr. Zhang of Tianjin Medical University. Vorinostat (SAHA, MK0683) purchased from Selleck
Method Western blot
Cell Lines MDB-MA-231 cells
Concentrations 0-20 μM
Incubation Time
Results

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related HDAC Products

  • LMK-235

    LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.

  • CAY10603

    CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.

  • 4SC-202

    4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.

  • Panobinostat (LBH589)

    Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

  • Entinostat (MS-275)

    Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

  • Trichostatin A (TSA)

    Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

  • Romidepsin (FK228, Depsipeptide)

    Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

    Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.

  • RGFP966

    RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.

  • Tubastatin A

    Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold).

  • Mocetinostat (MGCD0103)

    Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Phase 2.

Recently Viewed Items

Tags: buy Vorinostat (SAHA, MK0683) | Vorinostat (SAHA, MK0683) ic50 | Vorinostat (SAHA, MK0683) price | Vorinostat (SAHA, MK0683) cost | Vorinostat (SAHA, MK0683) solubility dmso | Vorinostat (SAHA, MK0683) purchase | Vorinostat (SAHA, MK0683) manufacturer | Vorinostat (SAHA, MK0683) research buy | Vorinostat (SAHA, MK0683) order | Vorinostat (SAHA, MK0683) mouse | Vorinostat (SAHA, MK0683) chemical structure | Vorinostat (SAHA, MK0683) mw | Vorinostat (SAHA, MK0683) molecular weight | Vorinostat (SAHA, MK0683) datasheet | Vorinostat (SAHA, MK0683) supplier | Vorinostat (SAHA, MK0683) in vitro | Vorinostat (SAHA, MK0683) cell line | Vorinostat (SAHA, MK0683) concentration | Vorinostat (SAHA, MK0683) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us